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Surface Plasmon Resonance imaging (SPRi) is a label-free, ultrasensitive 
detection method for monitoring biomolecular interactions in real-time with high 
throughput.   Diagnostic biomarkers for cancer, cardiovascular disease, and Alzheimer’s 
disease are often in low abundance in serum, presenting many challenges for their 
detection. SPRi has great potential as a diagnostic tool because its limit of detection 
(LOD) for many biomarkers falls in the nanogram per milliliter range, but in order to 
further enhance its usefulness, its LOD must be reduced to even lower concentrations.  
We have developed a detection scheme that improves SPRi sensitivity by several orders 
of magnitude. This increase in sensitivity relies upon the integration of SPRi with 
nanomaterials and microwave-assisted surface functionalization. This approach makes it 
possible for the SPRi biosensor to detect C-reactive protein in spiked human serum at 
concentrations of 5 fg/ml or 45 zeptomole. This scheme was then compared to 
commercial ELISA kits for the detection of human Growth Hormone, which has a LOD 
of 1 ng/ml.  In order to directly compare the two platforms the antibody sandwich assay 
was copied in the SPRi scheme and with nanomaterial enhancement, an LOD of 9.2 
pg/ml was achieved.
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CHAPTER I 
INTRODUCTION 
I.1 Proteomics 
The study of proteomics focuses on the characterization of a wide range of 
proteins in a system as small as a cell and up to the organism level.
1
  Proteomic studies 
take a complete protein profile and study the protein interactions in the sample.
2
 One of 
the major difficulties in proteomic research is the constantly changing protein levels that 
occur due to environmental changes, drug exposure and overall health of the system.
3
 
The constantly changing proteomic profile has led to the discovery of biomarkers that can 
be associated with specific diseases.  The ideal biomarker would be molecules in bodily 
fluids including proteins,
4-6
 antibodies,
7
 enzymes,
8
 and antigens
9
 that are only present 
when a disease is present.  However, this is not the circumstance in most cases and the 
only indicator of a disease is a change in concentration of the markers occurs, indicating a 
diseased state is present. A major source for proteome containing samples is serum, 
which maintains direct contact with all tissue in the system and contains a wide variety of 
proteins and other biological markers released from cells all over the body.
10,11
  Proteins 
will be present in the blood ranging from concentrations of milligrams to picograms per 
milliliter in serum.
12
  Detection of biomarkers in a complex media (serum or other bodily 
fluid) will mask the low abundance proteins which necessitates the usage of highly 
sensitive and specific detection platforms.
13,14
   Biomarkers are typically identified 
2 
 
by mass spectrometry which allow for detection of hundreds of proteins simultaneously 
and these biomarkers are then detected quantitatively by immunoassays such as enzyme-
linked immunosorbent assays (ELISA) and Western blots.  The primary tool of 
biomarker identification is the mass spectrometer coupled with a gel based or non-gel 
based separation technique. Mass spectrometry is an analytical technique that detects 
analyte ions relative to their mass to charge ratio.   The analyte will first be ionized by 
electron or atom impact, electrospray ionization (ESI) or by matrix-assisted laser 
ionization (MALDI). The ionization source chosen depends on the amount of 
fragmentation needed for the experiment as atomic or electron impact will cause greater 
fragmentation than ESI and MALDI.
15
  When ionizing an analyte with ESI, the sample is 
in a liquid medium that is transferred over to a gas phase by spraying the liquid through a 
high voltage needle.  The high voltage needle will fragment the analyte producing many 
different ions.
2
 MALDI ionization requires the target analyte to be mixed into a solution 
of organic acids.  The organic acid and analyte mixture is then crystallized onto a metal 
surface.  A laser source is then used to excite the matrix of acid and analyte causing the 
analyte to be released from the matrix as a gaseous ion.
2
 Once ionized, the analyte will be 
directed toward a mass analyzer/detector, most commonly a quadrupole or time of flight 
(TOF), which can determine the mass of the ion if the charge is known.  The quadrupole 
detector consists of four parallel rods that are electrically coupled in diagonal pairs.  A 
radio frequency is then imposed onto the charged rods, which will focus ions of a certain 
mass into the center of the four rods.  This frequency can be modulated such that only 
this specific mass to charge ratio ion is allowed to pass through the quadrupole and enter 
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the detector.
16
  Unlike quadrupole instrumentation that only allows a certain mass to 
charge ratio to pass, TOF analyzers use an electric charge to accelerate all ions toward the 
detector.  The different masses are then detected by comparing mass to charge ratio to the 
travel time of the ion.  All ions are accelerated with the same amount of energy which 
causes the lower mass ions to travel faster toward the detector and larger ions to have a 
slower velocity.
17,18
  In the detector the ion will be detected by an electron multiplier in 
which the charge of the ion will initiate a series of interactions that multiply the 
electronic signal to values that can be easily measured.  Tandem mass spectrometry also 
allows for certain ion mass to charge ratios to be isolated.  Once isolated these ions are 
impacted with another electron or atom causing the analyte to fragment further.  This 
second fragmentation allows for further details about the analyte structure to be 
determined.   
Mass spectrometry is typically used in proteomic biomarker discovery because 
the technique allows for a wide array of proteins to be detected and quantified 
simultaneously. (resulting from individual mass detection typically originating from 
individual proteins)  In  biomarker discovery, mass spectrometry is used to compare a 
diseased sample to that of a healthy control, which allows the detection of proteins 
present only in the diseased sample and comparison of protein concentrations.
19
   
The two main ways of determining the presence of biomarkers are the top-down 
and bottom-up methods.  The top-down method relies upon the detection of intact 
proteins, whereas the bottom-up method relies upon the detection of specific peptide 
sequences.  Top-down proteomic profiling is typically performed using either a gel-based 
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or non-gel-based separation. The conventionally performed technique uses two-
dimensional gel electrophoresis in which samples are separated. Individual spots can then 
be selected and mass spectrometry used for protein identification.
20
  Another top-down 
proteomic method is MALDI-MS in which biological fluids will have proteins extracted.  
These extracted fluids will then be mixed into a matrix and MALDI-MS can be 
performed.  One benefit of this process is that a tandem MS/MS run can be performed in 
order to further identify proteins of interest.
19
  Alternatively bottom-up proteomic 
identification is performed by using trypsin to cleave protein chains into short peptide 
sequences.  The now-digested sample can then be identified by mass spectrometry and 
the sequence analyzed.  The analyzed sequence can then be compared to full sequences, 
allowing for determination of the intact protein.   This process has a few drawbacks in 
that the complex nature of biological fluids is increased due to the trypsin treatments and 
less abundant proteins will be less likely to be enzymatically cleaved.
15
  Once potential 
biomarkers are identified by either method they must be verified to determine efficacy of 
these markers.  Verification can be performed by analyzing a large number of known 
control and diseased samples, the markers will then be used to determine which category 
the sample is in.  The accuracy of the predicted diseased state will then be used to 
determine if the biomarkers allow for accurate diagnosis. These biomarkers can then be 
studied further with quantitative immunoassays that allow for precise measurement of 
concentration.   
One of the most used quantitative immunoassays, ELISA was first developed in 
1971
21,22
 and was originally designed as an alternative to radioimmunoassays in which 
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radioactive tags were used to determine analyte concentration.
23
  There are many types of 
ELISA protocols such as direct, indirect or sandwich assays but all rely on the use of an 
enzyme to determine the concentration of the target analyte.  Generally, capture 
antibodies are immobilized onto a microplate that will later be used to adsorb antigen and 
detection antibodies on the surface.
22
  The enzyme will be used to react with an injected 
substrate that can easily be detected by a fluorometer or a UV-Vis in which the intensity 
of the signal will directly correlate with the analyte concentration.    
Direct ELISA, originally designed in 1971
22,21
 is used to detect and determine the 
concentration of high molecular weight proteins and antibodies.  The target protein 
analyte will be tagged with an enzyme, which will later be used to determine the 
concentration of the bound analyte.  This technique can also be used to detect the 
concentration of antibodies by coating the microplate with an antigen and incubating with 
an enzyme-labeled antibody.  In both cases, the enzyme will then be exposed to a 
substrate to determine the concentration.
24,25
  Direct ELISA later inspired the 
development of the indirect method in 1978.
26
  This method unlike the previous one, uses 
only antigen bound microplates, and antigen specific antibodies containing serum will be 
injected into the well to allow for antibody-antigen complex formation.  The unbound 
antibodies and serum proteins are removed from the well and an enzyme-labeled 
secondary antibody will bind the already bound antibodies.  This will then be used to 
react with the substrate to determine antibody concentration.
23
 
The most commonly used ELISA is the sandwich assay that was developed in 
1977.
27
 This technique uses antibody-labeled microplates to detect proteins in complex 
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media.  The analyte-containing samples are injected onto the plate, the protein is allowed 
to bind to the surface and any unbound proteins will be washed away.  A secondary 
detection antibody labeled with a biotin tag is then allowed to bind to the target protein.  
This step, unlike the previous two methods of ELISA, sets up a self-verifying step in the 
protocol by relying on multiple antibody-to-protein binding steps which decreases the 
possibility of false positives. A streptavidin-labeled enzyme binds to the biotin-labeled 
secondary antibody which converts a target substrate to a product that can then be 
measured by fluorescence or absorption.
28
   When using overnight incubations for the 
ELISA process the limit of detection is in the femtomolar (10
-15
) range.
29
   
 
 
 
Figure 1.1. Schematic of Enzyme-Linked Immunosorbent Assay   
 
 
A similar immunoassay, the Western blot, is another commonly used quantitative 
detection platform was first used by Towbind in 1979.
30
  The technique uses gel 
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electrophoresis to separate multiple protein samples based on molecular weight and 
electrical charge.   In order to remove bias based on secondary and tertiary structures the 
proteins are first treated with strong reducing agents to denature the proteins.
31
  The 
denatured proteins are then injected into a polyacrylamide gel where the proteins are 
separated by mass and charge.
32
 The gel is then placed into an electrical bias where a 
positive charge will attract the proteins in the sample (smaller molecular weight proteins 
will migrate faster than the larger proteins).  Sample(s) are loaded into the gel along with 
a standard containing multiple proteins with known molecular weights, stained with 
visible dyes, in order to see how far each molecular weight band has migrated.
31
  Once 
separation has occurred, the protein bands are transferred to a nitrocellulose membrane.   
The membrane and the polyacrylamide gel are placed together and an electric charge is 
placed in the z-axis to migrate the proteins off of the gel and onto the membrane where 
they will bind via hydrophobic interactions and hydrogen bonding.  The membrane will 
then be blocked to prevent nonspecific interaction by soaking in a solution of albumin 
from bovine serum (BSA).  After rinsing the membrane, a primary antibody is allowed to 
bind to the target analyte followed by a horse radish peroxidase-labeled secondary 
antibody.   The horse radish peroxidase is then exposed to a chemiluminescent agent to 
produce a light emitting product in proportion to the concentration of the analyte.
31
  This 
can be used along with a photographic film to produce an image of the emission showing 
intensity.
33
 The intensity of the emission can be compared to standards in order to 
determine analyte concentration. 
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New immunoassays, such as surface plasmon resonance, have been developed 
that allow for optical detection of binding events of protein analytes to detection probes.  
This platform allows for real time, label free detection as well as simultaneous measuring 
multiple biomarker interactions simultaneously.   
I.2 Surface Plasmon Resonance  
I.2.1 Introduction 
Surface Plasmon Resonance (SPR) is a label free, real time, sensitive, high 
throughput detection platform for biological interactions. The first observation of surface 
plasmons was in 1902 by Wood
34
 and the first excitation of surface plasmons was 
through coupling of light to an attenuated total reflection (ATR) by Otto and 
Kretschmann.
35,36
  Further applications by Liedberg et al. demonstrated the first usage of 
surface plasmons to detect biological interactions.
37
  
 The SPR biosensor relies upon the generation of surface plasmons at the interface 
between gold and aqueous dielectric.  A polarized light is shone on a gold coated prism 
and at a resonant angle where the x wavevector of the light resonate with the free 
electrons at the gold/dielectric interface, the photons are absorbed by oscillating electrons 
called surface plasmons.  The specific angle of light that is absorbed by the surface 
plasmons is dependent on the dielectric constant of the aqueous media above the gold 
surface.
38,39
 Any change to the surface, such as a binding event or temperature change 
causes a change in the dielectric constant of the media and consequently a shift in the 
angle of absorption.   
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Figure 1.2. Surface Plasmon Absorption and Reflectance Change. (left) Absorption peak 
of the surface plasmons showing the shift in angle of absorption due to binding event on 
the surface. (right) Kinetics graph representing the increase in signal corresponding to the 
shift in absorption 
 
 
This shift in SPR absorption can then be used to determine the kinetic information of a 
binding event on the surface of the gold (Fig 1.2).  When monitoring biological 
interactions, the intensity of light at the angle with the highest slope of the absorption 
peak is tracked over time, and is plotted to show any change of refraction.  The changes 
in refractive indeces are detected by the surface plasmons through an evanescent wave 
created by the electromagnetic field of oscillating electrons on the gold surface.  This 
wave decreases in intensity exponentially as the distance away from the gold surface 
increases (Fig 1.3).
40
 Consequently, a binding event that occurs closer to the gold surface 
will result in a higher signal than if the event was further away from the surface.   
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Figure 1.3. Evanescent Wave of Surface Plasmon Resonance 
  
 
I.2.2 Surface Plasmon Resonance imaging configuration 
The most used configuration of SPR is the Kretschmann configuration instrument 
in which an ATR is employed to modulate the x-wave vector to match that of the surface 
plasmons.
41,38,39,42
   In this configuration the wave vector and phase velocity is altered by 
a high density glass prism.
42
  After passing through the high density glass, the polarized 
light has a wave vector that matches that of the surface plasmons on the gold surface and 
is absorbed by the oscillating electrons.  The configuration of SPR, employs a gold 
coated high density prism used in conjunction with multiple flow cells in which each 
flow cell is labeled with a separate capture probe. However, in a Surface Plasmon 
Resonance imaging instrument, the typical Kretschmann apparatus is integrated with a 
charge-coupled device (CCD) camera that allows for real time visualization of the chip 
surface.   
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Figure 1.4. Surface Plasmon Resonance Imaging Configuration. (left) SPRi configuration 
showing the multiplexing capabilities to simultaneously detect interactions of multiple 
detection probes. (right) Difference image showing contrast change corresponding to 
specific binding to analyte-specific probe. 
 
 
When integrated with a CCD camera, multiple capture probes to be spotted onto the chip 
and due to this visualization of the chip a single flow cell is used.  When biomolecular 
interactions occur causing a signal increase from a change in reflectivity occurs which 
can then be correlated with a difference image (Fig 1.4).  The imaging aspect of SPRi 
allows for multiple interactions to occur simultaneously with the added benefit of visual 
validation with the difference image.   
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I.3 Sensor Functionalization 
In order to take advantage of the SPRi detection platform, the gold surface of the 
prism must be chemically modified to detect analytes.  This specific interaction between 
the surface and analyte is typically performed by reacting detection probes with the 
surface by the use of chemical linkers.  The detection probe must be close to the gold 
surface, (in the evanescent wave region of the sensor) to allow for maximal refractive 
index changes during analyte binding.  Additionally, the surface must be designed to 
block non-specific interactions while not reducing the binding efficiency of the target 
analyte to the sensor.  
I.3.1 Self-Assembled monolayers 
One of the most used chemical linkers, thiol modified alkane derivatives, can be 
used to form self-assembled monolayers (SAMs) on the gold surface.  The molecules will 
arrange into an ordered layer in which the thiol functional group will react with the 
surface in a highly ordered fashion with minimal defects.   The SAMs are usually formed 
with bifunctionalized alkanes, which can have any functional group on the alkane tail 
group allowing for further functionalization to occur.  Bifunctional linkers such as 11-
mercaptoundecanoic acid, attach the thiol functional group to the gold surface and create 
a surface with free carboxylic acids.  The carboxyl surface can then be activated by the 
usage of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and n-
hydroxysuccinimide (NHS) to form a highly amine-reactive surface.   
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Figure 1.5. SPRi Surface Chemistry 
  
 
The activated surface can then be reacted with amine containing proteins, antibodies or 
molecules that allow for label free detection of the targeted analyte.  
I.3.2 Antibodies 
Immunoglobulins that have strong binding affinities to antigens are known as 
antibodies.  Antibodies have a Y-shaped structure formed by two identical halves made 
up of a heavy chain (~55 kD) and a light chain (~25 kD) that are bound together by 
disulfide and hydrogen bonding.   Antibodies have similar heavy chain structure and the 
light chain is specifically modified to bind to a target antigen.  The two main classes of 
antibodies are polyclonal antibodies and monoclonal antibodies and are used for 
biological and medical research.
43
  Production of polyclonal antibodies begins with a 
14 
 
purified solution of the target antigen (analyte) that is injected into a lab animal (typically 
mice, rats, or rabbits) in order to induce an immune response toward the antigen. It is 
important to inject an appropriate amount of the antigen because too low a dose will not 
induce an immune response and too high will cause unwanted side effects to the animal.
44
  
The antigens can be injected by various means including, but not limited to, 
subcutaneous, intradermal, and intravenous. These injections can be performed by either 
injecting one large volume or multiple small volume injections.
43
  After antigen 
injection(s) are performed, blood draws are performed to monitor the antibody response 
in blood serum. Once appropriate levels of antibodies are achieved in the blood the 
animal, the animal is sacrificed via heart puncture and antibodies are purified from 
serum.
43
  
In 1975, monoclonal antibodies were produced back by fusing a B cell, which 
produces a single variety of antibody, with a myeloma cell, thus immortalizing the cell 
and allowing for production of a hybridoma (Fig 1.6).  The hybridoma could produce vast 
quantities of monoclonal antibodies.
45
  Production of monoclonal antibodies, unlike 
polyclonal, use Bagg albino (BALB/c) mice for antibody production since the majority of 
myeloma cells are produced by this strain of mouse.
43
   The overall procedure is similar 
to production of polyclonal antibodies, except that antibodies are not harvested from the 
serum.  In this case, B cells are harvested from the spleen of the animal and individual 
cells are fused with nonsecreting myeloma cells.
43
 The cells are then allowed to 
proliferate, and the resulting antibodies produced by the hybridomas are tested for 
specificity.  
15 
 
The choice to use a monoclonal or a polyclonal antibody is dictated by factors 
such as time, cost, and binding locations.  During the production of an antibody, the 
technical skill required to produce monoclonal antibodies is much higher than polyclonal. 
In addition, the polyclonal process takes a few months compared to a yearlong process 
for the production of sufficient quantities of monoclonal antibodies.   There will be less 
variability between batches of monoclonal antibodies due to their production from a 
cloned hybridoma and will only target a specific epitope on an antigen.
46
  This specificity 
in epitope targeting can create a problem if there is slight structural changes in the 
epitope location binding will be limited.  This can be overcome by the use of polyclonal 
as multiple binding sites can be targeted simultaneously.  Overall the choice of polyclonal 
or monoclonal will depend on the application.  
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Figure 1.6. Monoclonal Antibody Production Method.  The antigen is injected into an 
animal to induce an immune response.  B cells are harvested and fused with myeloma 
cells to form an antibody forming hybridoma. The cells are allowed to proliferate, 
forming monoclonal antibodies. 
 
 
I.3.3 Aptamers  
In 1990 it was discovered that unique sequence with high affinities for target 
analytes could be produced by using large libraries of nucleic acid sequences.
47
 This 
process would later become known as systematic evolution of ligands by exponential 
enrichment (SELEX).  This process allows for the production of aptamers which are 
synthetic DNA or RNA sequences that have been selected to have high affinity for a 
target analyte (Fig 1.7).   The analyte is initially incubated with a pool of 10
14
 different 
nucleic acid sequences during which only a small portion will bind.  The diversity of the 
library used will dictate the number of unique sequences that will bind the analyte and 
17 
 
increase the chance of finding an extremely high affinity aptamer.
48
  After the binding of 
the aptamer and analyte has occurred, the unbound DNA sequences are removed by 
physical separation techniques such as nitrocellulose membrane filtration
49
 or the analyte 
can be prefunctionalized to magnetic beads and magnetic separation can be performed.
50
 
After separation, the bound sequences are eluted off of the analyte and are then amplified 
through polymerase chain reaction.  This process will be repeated for 8 to 15 rounds, 
depending on the target, resulting in a few high affinity aptamers that are highly specific 
toward the analyte.
50
 
The single stranded aptamer sequences are able to bind a wide variety of analytes 
due to the many secondary and tertiary structures that they can form.  Aptamers have a 
wide variety of structures due to their ability to form not only Watson-Crick base pairing 
but also many other unusual pairing methods.
51
 Currently, aptamers have been shown to 
bind to many analytes including, but not limited to, metal ions,
52,53
 amino acids,
54-56
 
antibodies,
57
 and peptides.
58,59
 One factor that allows for aptamers to bind to most any 
analyte is their ability to detect the presence of small groups such as methyl,
60,61
 
hydroxyls,
62,63
 or even enatiomeric changes.
64
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Figure 1.7. Systematic Evolution of Ligands by Exponential Enrichment.  Aptamer 
production begins with a nucleic acid library being incubated with a magnetic-bead-
labeled target analyte.  The bound sequences and protein are removed from unbound 
sequences and are then amplified by polymerase chain reaction. The process is then 
repeated multiple times 
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Table 1.1. Comparing Antibodies to Aptamers 
 
 
I.3.4 Blocking agents 
In order to prevent non-specific interactions between the analyte and the gold 
surface of the sensor, the prism must have additional blocking agents to fill in gaps in the 
surface functionalization.   Blocking agents can be comprised of thiolated polyethylene 
glycol or thiolated alkanes which react with the surface using SAM chemistry.  In 
addition to direct chemical binding to the surface, protein blocking agents such as BSA or 
casein can be bound through non-specific electrostatic interactions.   
 
 
  Antibodies Aptamers 
Target analytes 
Limited : only analytes that have 
immune response 
Unlimited  
Buffer restriction 
Limited : Restricted to buffers 
similar to body conditions 
Unlimited : SELEX can be 
performed in any buffer 
Temperature 
stability 
Irreversible denaturation  Reversible denaturation 
Chemical 
Modification 
Limited : can occur in multiple 
locations 
Easily modified at specific 
locations 
Time requirements 
Slow : Polyclonal antibodies can 
be produced in a few months and 
monoclonal can take upwards of 
a year 
Fast : SELEX process takes a few 
weeks 
Size 12-15 nm 3-5nm 
Composition Protein Synthetic nucleic acids 
Batch to batch 
reproducibility 
Polyclonal antibodies will vary 
widely batch to batch, 
monoclonal will have minimal 
variation due to production from 
cloned hybridomas 
Produced via chemical reaction 
with high precision 
Binding affinities high binding affinity Similar to Antibodies 
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Figure 1.8. SPRi Blocking Agents   
 
 
Either SAM or electrostatic binding process can be used to limit serum and/or 
analyte’s non-specific interactions with the gold surface.   In addition to minimizing the 
non-specific interactions, these blocking agents must not interfere with specific analyte to 
detection probe interactions.   
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CHAPTER II 
A REVIEW OF METHODS OF AMPLIFICATION  
The surface plasmon resonance imaging detection platform senses binding event 
by detecting the changes in the local dielectric above the gold surface.  When the 
concentration of the analyte is high, the initial binding to the detection probe results in a 
change that is able to cause a discernable signal, distinguishable from a negative control 
(Fig 2.1 left). However, when attempting to detect analytes at lower concentrations, 
(lower than the detection limit of the instrument) the change is insufficient to cause a 
significant signal.  In order to detect these low levels of analyte a method of amplification 
must be implemented to increase the sensitivity of the platform.   
 
Figure 2.1. Detection Schematics of SPRi. (left) Schematic showing the unamplified 
direct detection of analyte. (center) Label free method of incorporating nanoparticles onto 
the gold surface for means of amplification. (right) Labeling method in which a 
nanoparticle is labeled with an antibody and then the complex is bound to analyte to 
significantly amplify signal. 
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II.1 Gold Nanoparticles 
Gold nanoparticles have been extensively studied for integration into the SPRi 
system due to their ability to vastly increase sensitivity and the limit of detection of the 
platform.  The use of gold nanoparticles was first implemented in 1998 when 11 nm gold 
nanoparticles were used in a sandwich immunoassay to amplify the detection signal of 
immunoglobulin G was increased 25 fold.
65
  Many studies on the usage of gold 
nanoparticles have been performed to determine the mechanisms behind this 
amplification.  These nanoparticles, unlike their bulk counterparts, exhibit localized 
surface plasmon resonance (LSPR) which results in a UV-Vis absorption.
66,67
  The peak 
of the absorption band of the LSPR can be tuned by altering the nanoparticle size,
68,69
 
shape,
68,70
 coverage density
65,71,72
 and distance from the gold surface.
73,74
   The suggested 
mechanism for the signal amplification is that the LSPR of the gold nanoparticles 
resonate propagating surface plasmons on the gold surface of the platform.
75
   
Gold nanospheres are typically used for labeling analytes, however, gold 
nanorods allow for greater tuning of the absorption wavelength.
76
  A nanorod is a particle 
in which the ratio of length to width is between 1 and 20 in which oscillations of the 
surface plasmons occur in both the transverse and longitudinal directions.
77,78
  This ratio 
and particle size can thus be used to tune the nanorods to interact with the SPRi detection 
platform’s commonly used laser wavelengths. 
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Gold nanospheres are synthesized using a citrate reduction in which a solution of 
tetrachloroauric acid solution is heated to 97 ºC followed by addition of trisodium citrate 
inducing growth of nanocrystals. 
79
  As time passes, the solution turns bright red.  The 
size of the nanoparticles can be tuned by altering the ratio of tetrachloroauric acid to 
trisodium citrate where a higher ratio results in larger nanoparticles.
80
 The resulting 
nanoparticles retain a strong negative charge from the citrate ions. This negative charge 
results in water-soluble nanoparticles that can then be used in biological applications.   
Gold nanorods can be formed by using smaller sized gold nanospheres as a seed 
material.  The seed material can then be added to a solution of cetyltrimethylammonium 
bromide (CTAB), tetrachloroauric acid, and ascorbic acid to form larger cubes, rods, or 
star shaped nanoparticles depending on the ratio of the components.  The formation of 
these shapes results from growth kinetics being altered by the stabilizing agents.
81-83
  For 
example 95 mM CTAB solution with a ratio of ascorbic acid to gold ions maintained at 
1.6, the resulting nanoparticles will be rod shaped nanoparticle ranging from rectangular 
shaped to cylindrical rods depending on the seed concentration.
84
 
II.1.1 Gold nanoparticle label free detection 
Label free amplification of the SPR signal is one of the easier methods of 
amplification of signal due to its direct detection of the target analyte.  The surface is 
modified by immobilizing gold nanoparticles on to the gold surface (Fig 2.1 center).  This 
method is considered direct detection method as the signal increase only originates from 
analyte binding to the detection probe.  The increase in sensitivity is theorized to be due 
to the accessibility of the detection probe due to the coupling of the LSPR of the 
24 
 
nanoparticles
69,72,85,86
 and the propagating surface plasmons of the surface and now non-
planar detection surface.
74,87,88
   
Gold nanoparticles are immobilized on the gold surface by use of self-assembled 
monolayers in which dithiols can be used to coat the gold surface followed by deposition 
of the nanoparticles.  The enhancement implemented by direct SAM attachment of gold 
nanoparticles was tested by Ko et al in which two substrates were compared.  In one case 
gold-binding modified protein A was bound to bare gold and to 25 nm gold nanoparticles 
immobilized onto the gold surface by 2-aminoethanethiol.  The two surfaces were then 
exposed to human immunoglobulin G and then anti-immunoglobulin G.  The bare gold 
surface and the gold nanoparticle treated surface resulted in 92% and 32% higher signal 
respectively.
89
 
Recent studies have shown that the usage of dielectric layers such as silicon 
dioxide acting as a spacer between the gold nanoparticle and the gold surface will allow 
for higher electron tunneling, which results in an induced shift in the SPR absorption 
caused by stronger coupling between the LSPR and surface plasmons.
90
   In the study by 
Jung et al
91
 this theory was tested by comparing detection of prostate specific antigen 
(PSA) on gold substrates and silicon dioxide coated gold substrate with and without gold 
nanoparticles.  The silicon dioxide layer was formed on the gold substrate by using 
mercaptosilane to act as an adhesion layer for the oxide layer.  The oxide layer was 
formed by immersion in a sodium silicate solution and was followed by immobilization 
of 5 nm gold nanoparticles using amine labeled organosilane.  In order to determine the 
effectiveness of the amplification of the oxide layer and gold nanoparticle  surface, anti-
25 
 
PSA was immobilized onto the three substrates (gold surface, silicon dioxide coated gold 
surface, and gold nanoparticle/silicon dioxide coated gold surface).  In the case of  bare 
gold, the detection platform was unable to detect PSA at a concentration of 100 ng/ml; 
however, the gold nanoparticle and oxide labeled surfaces were able to effectively detect 
PSA down to 0.1 ng/ml (5 fold increase in sensitivity over an oxide coated gold surface at 
1 ng/ml).
91
  
II.1.2 Gold nanoparticle sandwich detection 
The more sensitive amplification method employs gold nanoparticles as a 
sandwich assay detection probe, which vastly increases the sensitivity of the technique, 
but transforms the label free SPR detection to a labeled method.  In the sandwich 
detection method, much like ELISA assays, the target analyte will first bind to the 
detection probe immobilized onto the gold surface.  A nanoparticle labeled with a 
detection probe will then bind to the analyte.  This binding event will increase the 
sensitivity of the instrument by increasing the overall mass attached to the gold surface 
and a coupling event between the LSPR and surface plasmons of the gold surface will 
occur.  
The increase in sensitivity from usage of the gold nanoparticle enhance sandwich 
assay was tested by Liu et al in which the direct detection of human complementary 4 
protein was compared to the limit of detection of the sandwich technique.
92
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Figure 2.2. Gold Nanoparticle Amplified Detection of Human Complementary 4.  (top) 
Schematic of the direct detection of Human C4 using an antibody labeled gold surface. 
(bottom) Sandwich amplification of the human C4 binding event using 10 nm gold 
nanoparticles. 
 
 
Human C4 antibody was used as the detection probe in both the direct detection and 
sandwich assay (Fig 2.2).  The direct detection of the C4 protein resulted in a limit of 
detection of 2 ug/ml.  In the gold nanoparticle enhanced sandwich assays, human C4 
protein was injected onto the gold surface followed by secondary antibody-labeled gold 
nanoparticles and another injection of C4 protein.  After amplification, the limit of 
detection for the protein was determined to be 0.05 ug/ml, a 40-fold increase in 
sensitivity.
92
 
The usage of gold nanoparticles has also been applied to the detection of micro 
RNA (miRNA)  by the Corn group in 2006.
93
 In this study, locked nucleic acids (LNA) 
were used to detect the presence of miRNA (Fig 2.3).  In order to amplify the sensitivity 
of the signal, multiple means of amplification were employed. After the initial 
hybridization of the miRNA to the LNA, the 3’ end of the miRNA would be 
27 
 
polyadenylated by exposure to poly (A) polymerase.  The addition of the adenosine 
residues would increase the resulting signal from the miRNA by 11 fold.  
  
 
Figure 2.3. Amplified Detection of Locked Nucleic Acids. Schematic showing the 
binding event of the miRNA to the LNA detection probe. Followed by the amplification 
steps of poly(A) polymerase and finally exposure to thymine labeled gold nanoparticles. 
 
 
The now adenosine labeled miRNA would be further amplified by the addition of 
thymine (30) labeled gold nanoparticles.
93
  After dual amplification of the miRNA 
samples, the limit of detection was determined to be 10 fM or a 10
5 
signal enhancement 
from the groups previously reported limit of detection.
94
 
Unlike previous amplification methods the Lee group investigated the use of both 
a gold nanorod and a gold nanosphere. In this study, they were able to detect 
subattomolar concentrations of thrombin protein.
95
  This protein was chosen because 
there was readily available antithrombin and thrombin specific aptamers that have 
separate binding locations.  
28 
 
 
Figure 2.4. Detection of Thrombin with Dual Amplification.  Schematic showing the 
initial direct detection of thrombin by anti-thrombin followed by amplification by the 
secondary binding of the aptamer.  This aptamer was then used to capture the 
polythymine labeled nanorod and then the polyadenine-labeled gold nanosphere. 
 
 
In this study, the analyte was allowed to bind to the anti-thrombin labeled SPR surface.  
Following the specific interaction between the antibody and protein the poly adedenine 
labeled thrombin specific aptamer was allowed to bind to the free epitope site.  This 
aptamer functioned  as a binding site for the dual nanoparticle amplification in which the 
adenine and thymine hybridization was used to bind the gold nanorod and followed by 
secondary binding of the gold nanosphere.  As a result of the dual nanoparticle 
29 
 
amplification, the limit of detection of thrombin was 0.1 aM,
95
 which is a 10 fold 
improvement over the previously reported limit of detection in which nanospheres were 
used as a single nanoparticle amplification system.
96
 
Enhancing the amplification resulting from gold nanoparticle sandwich assays not 
only depend on the nanoparticles used but can also depend on the detection and capture 
probes used.  In the study by Kim et al. the properties of the probes was tested by 
comparing the amplification resulting from the use of an aptamer and antibody as a 
detection probe.
97
 The two binding protocols were performed on IgE in which there was a 
binding location for both the antibody and aptamer that do not interfere with the other.  
After IgE was bound a 13 nm gold nanoparticle labeled with aptamers in the case of the 
antibody detection probe and vice-versa was used to amplify signal.  
 
 
Figure 2.5. Detection Probe Comparison.  (left) Graphical representation of the IgE 
bound to the antibody detection probe and signal amplification with an aptamer labeled 
gold nanoparticle and (right) IgE bound to the aptamer detection probe and a sandwich 
assay performed with antibody labeled gold nanoparticle. 
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After optimization of the two surfaces, it was shown that in the case where the aptamer 
was used as the detection probe the signal resulting from the amplification resulted in 
over a 10 fold increase in signal.  In both cases the increase in sensitivity was 10
6
 
increase in sensitivity compared to unamplified direct detection of IgE.
94
 
II.2 Quantum Dot Amplification 
Quantum dots (QDs) are a special class of inorganic semiconductor nanoparticles 
that are composed of II-VI, III-VI, and IV-VI periodic groups.  The particles have a 
diameter ranging from 2 to 10 nm.
98
   QDs have many special features that arise from a 
property known as quantum confinement and this property in semiconducting 
nanoparticles has been extensively studied.
99,100
 The quantum confinement is caused by a 
widening of the band gap between the conduction and valence band as the nanoparticles 
decrease in size.
101
  This effect can be seen by comparing the emission of differently 
sized QDs.  QDs have an electron in the valence band that is excited to the conduction 
band by a photon in the ultraviolet region.  As the excited electron returns to the valence 
band, a photon of visible light will be released through radiative decay.  Larger QDs will 
release a red photon (low energy) and smaller ones will release a blue photon (high 
energy).  The size of the nanoparticles can thus be tuned to have a band gap that will 
correspond to the majority of the visible spectra. 
102,103
   
A typical synthesis method for QDs is hot injection method in which a solution of 
cadmium oxide, tetradecylphosphonic acid, and trioctylphosphine oxide (TOPO) are 
loaded into a 3 neck flask under inert atmosphere.  The solution is heated to 300 ºC and a 
solution of tellurium, selenium or sulfur dissolved in trioctylphosphine is injected at    
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270 ºC and nanocrystals are allowed to grow at 250 ºC.
104
 This reaction forms a 
monodisperse solution that is shown by a sharp absorption peak if the growing process is 
stopped in a time which there is limited size dispersion known as “focusing of size 
distribution.”
105
  These nanocrystals will be TOPO capped and will be soluble in organic 
solvents. For use in biological detection in SPRi, the TOPO ligands must be exchanged 
with polar ligands that will allow for highly water soluble particles that can interact with 
proteins in aqueous media.  One of the most used exchanges involves reacting the TOPO 
capped quantum dots with mercaptohexadecanoic acid (MHDA) under inert atmosphere.  
After cooling the mixture, dimethylformamide and potassium tert-butoxide are added 
resulting in water soluble MHDA-capped quantum dots.
106
 The now water soluble 
nanoparticles can be activated using EDC/NHS chemistry for easy labeling with 
streptavidin or antibodies for use in SPRi sandwich assays. 
II.2.1 Quantum dot sandwich assay 
In 2011, quantum dot amplification, via sandwich assays, were studied by Malic 
et al.
107
 In order to determine the effects of QDs on SPRi signal, the group immobilized 
thiolated DNA sequences (positive and control) onto a gold surface and the surface was 
blocked using heptadecafluoro-1-decanethiol.   The complementary DNA sequence that 
was previously biotin-labeled was hybridized to the DNA detection probe.  This direct 
detection of the biotin-labeled complementary DNA was amplified by two different 
schemes.  First the biotin-labeled DNA sequence was injected and allowed to hybridize 
and a streptavidin-labeled QD (5nM) was allowed to bind via biotin-streptavidin 
complex.  In the second case the biotin-labeled complementary DNA was reacted with 
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the streptavidin-labeled quantum dot and then the entire complex was injected over the 
surface and allowed to hybridize.  After comparing the two schemes, it was noted that in 
the first case, in which hybridization occurred followed by quantum dot amplification, 
that the signal increase was 15 fold and in the second case the amplification was only a 
10 fold increase.
107
  The amplification as with any sandwich assay for SPRi was in part 
due to the addition of the mass of the nanoparticle.  It was noted that QDs in proximity to 
gold surfaces will have an enhancement in fluorescence and this emission will be directed 
into the surface plasmons on the gold surface, further enhancing the amplification.
107,108
  
This idea was then tested by comparing the amplification of different emission 
wavelengths of QDs (525, 700, 780, 800 nm). The same experiments were performed as 
before, with hybridization occurring followed by injection of streptavidin-coated QDs.  In 
the cases of 525 and 700 nm emitting quantum dots, the amplification was less than 50% 
the intensity of the 800 nm quantum dot.   For the 780 nm quantum dots that have a mass 
nearly equal to the 800 nm quantum dot, the signal was reduced by 25%.  It was 
theorized that the higher amplification of 800 nm QDs, the emission was tuned to the 
absorption wavelength of the surface plasmons on the gold surface, thus allowing for 
easier absorption and greater signal enhancement.
107
  
After determining the optimal quantum dot emission, the LOD of DNA 
hybridization was determined to be 1 fM, 6 orders of magnitude better than previously 
reported.
109
  This effectiveness of this amplification was further tested for the LOD of 
PSA using anti-PSA immobilized onto the gold surface using prolinker B calixcrown 
chemistry and the surface was then blocked using BSA.  The direct detection of PSA by 
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the sensor was then determined to be 1 ug/ml and after amplification by detection 
antibody and quantum dot the detection limit was reduced to 100 pg/ml.  In order to 
determine the specificity of the amplification method, the group then tested for the 
detection of PSA in serum spiked with a known amount of PSA.  Due to serum proteins, 
the immobilization chemistry for anti-PSA and control antibodies was changed to a 
mixed thiol monolayer consisting of hydroxyl and carboxyl terminated polyethylene 
glycol to further reduce nonspecific binding.  The carboxyl groups were then activated 
via EDC/NHS chemistry and the antibodies were then immobilized onto the amine 
reactive surface and the surface was deactivated with ethanolamine.   Initial injection of 
PSA in 10% serum resulted in indistinguishable detection of PSA due to nonspecific 
binding of serum proteins.  In order to detect PSA proteins the surface was then treated 
with biotin-labeled detection anti-PSA and streptavidin-labeled QDs. This specific 
quantum dot amplification method resulted in a detection limit of 2.5 ng/ml PSA in 
spiked serum.
107
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CHAPTER III 
SYNTHESIS OF CARBON-COATED QUANTUM DOTS 
III.1 Introduction 
A special class of semiconductors composed of periodic group elements II-VI, III-
V and IV-VI, better known as QDs have unique optical properties such as size-dependent 
fluorescence and broad absorption spectra.
104
 Due to their unique photophysical 
properties, QD applications have exploded in various outlets such as solar devices,
110
 
electronics,
111
 solid state lighting,
112
 sensors
113
 and nanomedicine
114
. The latter 
application has presented some setbacks more specifically in employing QDs in vitro and 
in vivo, due to concerns about their toxicity because of their heavy metal constituents. 
Toxicity concerns have prompted researchers to develop protective coatings on the 
surface of QDs such as silica,
115,116
 proteins,
117
 polymers
118,119
 and gelatine.
120
 In addition 
to protecting the surface of the QDs, coatings should be readily accessible for additional 
functionalization to broaden utilization. Carbohydrates, in addition to their enormous 
roles in cellular recognition processes,
121
 serve as an attractive coating for nanoparticles 
because the availability of hydroxyl and carbonyl groups promote additional 
functionalization and facilitate hydrogen bonding that is useful in engineering smart 
nanomaterials.   For example, glucose-coated platinum nanoparticles were self-assembled 
to generate smart platinum nanowires. 
122
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Despite a large number of applications, there are only a few strategies for 
carbohydrate coating on QDs. For example, Kikkeri et al have developed galactose-
PEGylated QDs by using a short thiol spacer
123
 and mannose-coated QDs using a 
continuous flow microreactor.
124
 Another group utilized a “one pot self-assembly” 
procedure to engineer mannose-coated QDs to selectively detect E. coli strains.
125
 
Recently, Bavireddi et al used a host guest assembly to make glycolcyclodextrin capped 
QDs.
126
 In all the aforementioned strategies, pretreatment of carbohydrates with a 
reactive functional group is required. To date, there are no strategies that allow direct 
growth of carbohydrates on QDs. Here, we report for the first time a facile and direct 
approach for synthesizing carbon-coated QDs using microwave technology.  In brief, the 
method is based on microwave pyrolysis of sugars in the presence of water soluble CdSe 
QDs. This technique rendered QDs that could have great potential as tools for bioimaging 
applications and engineering smart nanostructures. 
III.2 Methods 
All reactions were carried out in a fume hood at standard temperatures and 
pressure. All reagents were purchased from Sigma-Aldrich, with exception to carboxyl-
PEG3000-SH-gold nanoparticles which were purchased from Cytodiagnostic Inc. 
III.2.1 QD synthesis 
Synthesis of CdSe QDs was based on a modified previously reported 
procedure.
127
 In a 50 ml round bottom flask, a mixture of cadmium acetate (13 mmol), 
trioctylphosphine oxide (TOPO) (13 mmol) and hexadecylamine (10 mmol) were 
irradiated in a CEM discover microwave reactor at 100 W to 100 ºC for 1min, followed 
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by a ramping up to 150 ºC for 1min and holding  at this temperature for 2min. The 
solution was then allowed to cool to 42 ºC. In a separate flask selenium powder (600 
µmol) was dissolved in 2 ml of trioctylphosphine and then introduced to the cadmium 
cocktail followed by irradiation at 100 W to 100 ºC for 1 min while stirring. The 
temperature was raised to 145 ºC and held for 2.5 min (variation of the final temperature 
and hold time influences the size of the QDs). Then, the solution was allowed to cool 
followed by adding an excess methanol in order to precipitate out the QDs. After 
centrifugation, the QDs were washed several times with methanol in order to remove 
unreacted starting materials. 
III.2.2 Water solubilazation of QDs 
Water solubilization was based on a previously reported method.
106
 TOPO ligands 
on CdSe were exchanged with mercaptohexadecanoic acid (MHDA) in situ under inert 
atmosphere at 90 ºC for 2h. Then, the reacting mixture was cooled down; 
dimethylformamide (600 µL) and potassium tert-butoxide were added to render the QDs 
water soluble. The resultant product was centrifuged and concentrated using a molecular 
weight cutoff filter of 30 kD. 
III.2.3 Carbon nanoparticles 
Carbon nanoparticles were prepared to serve as a control.  Carbon nanoparticles 
were synthesized by the methods previously reported by Chandra et al.
128
  
III.2.4 Carbon-coating of QDs and gold nanoparticles 
Reduction of sucrose on the nanoparticles as a coating material was assessed by 
varying the amount of sucrose to nanoparticles (1.33:1). In brief, sucrose (33 nM) was 
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dissolved in distilled water (1.7 ml) followed by the addition of 85 % orthophosphoric 
acid (100µL) and nanoparticles (QDs or gold, 25 nM). The reacting solution was 
irradiated at 100 W for 3 min 40s. The resultant solution was allowed to cool down to 
room temperature (25 ºC) and distilled water (4 ml) was then added. The solution was 
then centrifuged at 4000 rpm for 10 min pelleting the coated nanoparticles. The sugar-
coated nanoparticles were then washed three times with distilled water followed by 
centrifugation. Before dispersing in water, the coated nanoparticles were dried overnight 
in a vacuum oven at 40 ºC. 
III.3 Results 
III.3.1 Spectroscopic analysis of nanoparticles 
Small (3-4 nm) and large (7-8 nm) MHDA-QDs were synthesized in order to 
compare the influence of the carbon coating on their photophysical properties. A red shift 
in absorption peak was observed (see Fig 3.1) after carbon coating the small (10 nm 
wavelength shift) and large (4 nm wavelength shift) QDs. 
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Figure 3.1. Absorption Spectra of Quantum Dots and Carbon Nanoparticles   
 
 
The carbon absorption was also observed at 290 nm (see Fig 3.1). Interestingly, there was 
no change in emission wavelength; however, the emission intensity was enhanced. (see 
Fig 3.2) Assessed as a negative control, individual carbon nanoparticles did not emit light 
after excitation with a 350nm laser (see Fig 3.2). To demonstrate the versatility of the 
coating approach, we substituted the QDs with commercially available carboxyl-PEG 
(3000)-gold nanoparticles (Cytodiagnostic Inc., 10 nm) and citrate stabilized gold 
nanoparticles (Sigma Aldrich, 50 nm). After carbon coating, the carboxyl-PEG gold 
nanoparticles did not change the surface plasmon resonance (SPR) peak at 532 nm. 
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Figure 3.2. Emission Spectra of Coated and Uncoated Quantum Dots  
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Figure 3.3. Absorption Spectra of Coated and Uncoated Nanoparticles 
 
 
However, the citrate stabilized gold nanoparticles produced a small red shift in SPR peak 
after coating (see Fig 3.3, gray) and an additional broad absorption peak at 700 nm. The 
carbon peak at 290nm was more present in the citrate gold nanoparticles and was not 
observed with the carboxyl-PEG gold because in this region it has a strong absorption 
before coating (see Fig 3.3). 
III.3.2 X-Ray analysis of nanoparticles 
X-ray diffraction patterns of CdSe-TOPO (Fig 3.4, gray plot and inset) reveal 
peaks at (111), (220) and (311) indicating a zinc blende arrangement.  
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Figure 3.4. X-ray Diffraction Spectra 
 
 
After carbon coating, the CdSe nanoparticles peak are present in addition to prominent 
peaks pertaining to carbon coating (red). Serving as a control, XRD pattern was collected 
on carbon nanoparticles, clear sharp peaks support a non-amorphous material (black). 
III.3.3 Microscopic analysis of nanoparticles 
Transmission electron microscopy examined the morphological nature of CdSe 
before and after coating. The microwave synthesis of CdSe afforded highly uniform 
nanoparticles in the size range of 7-8 nm. It was observed that after coating with carbon, 
the diameter increased to around 14 nm (inset) with a gray halo around CdSe 
nanoparticles (see Fig 3.5). In addition, TEM images were collected on carbon coated 
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citrate stabilized gold nanoparticles which also showed a gray halo (see Fig 3.6, inset) 
and the diameter was around 60 nm. The thickness of the carbon coating was about 5 nm.
 
Figure 3.5. TEM Images of Carbon Coated Quantum Dots. 12-14 nm diameter at low 
magnification (100K) and high magnification (160K, inset). 
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Figure 3.6. TEM Images of Carbon Coated Gold Nanoparticles 
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III.4 Discussion 
Assessment of QD’s light absorption properties after carbon-coating revealed a 
red shift that can be interpreted as a change in the surface charge states of the QDs or to a 
change in the dielectric medium surrounding the nanoparticle surface. Also, after coating, 
we were able to verify the presence of carbon with an absorption peak at 290 nm. The 
emission properties of the QDs were enhanced after coating and the smaller QDs 
experienced a greater enhancement in comparison to the larger QDs. It is evident that the 
carbon coating has a greater influence on the photophysical properties of the small QDs 
as oppose to the large QDs. As the size of a QD decreases, there is an increase in the 
surface-area-to-volume ratio, making them more sensitive to any perturbation or 
modifications done on the surface. We postulate that the carbon coating minimizes 
surface defects and oxidation,
129
 which are well-known culprits in decreasing emission 
intensities in QDs. 
To further understand the above-mentioned phenomena after carbon coating, we 
evaluated the strength of confinement in our experiments, using estimates for effective 
masses of electrons (ms*=0.19), holes (mh*= 0.8) and the dielectric constant at optical 
frequencies (ε = 5.7) for the CdSe crystalline structures.
130
 For these parameters, the bulk 
Bohr exciton radius is approximately equal to 2 nm ensuring at least a moderate-
confinement regime for QDs smaller than 4 nm in diameter used in our experiments. 
Adding a dielectric layer due to carbon coating does not appreciably increase the radii of 
electron-hole excitons, but redistributes the electronic density in QDs toward the center 
due to discontinuity of the effective masses inside the dot and in the surrounding 
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dielectric layer. For the parameters mentioned above and the electron effective mass in 
amorphous carbon (ms*= 0.8),
131
 the mass discontinuity factor equal to the ratio of 
effective masses in the dot and dielectric layer amounts to a value of 0.25. This results in 
a shift of the peak corresponding to the electronic density from the QD surface to a half 
of its radius and effectively consolidating more charge carriers inside the dot, thus, 
further enhancing its quantum confinement.
132
 
Although we did not detect any substantial shift between spectra of the coated and 
uncoated dots, it was observed that coating brightened QDs, increasing the intensity of 
their emission spectra. The small QDs surface-area-to-volume ratio is sufficiently high 
and it is more likely for surface defects to trap electrons, preventing them from 
subsequent recombination which decreases intensity of photonic emission.  Our results 
are similar to other findings recently reported for small carbon-coated silicon particles
133
 
and passivated colloidal QDs.
110
 The latest suggests that carbon coating may significantly 
neutralize the trapping effect and would pave the road for developing the higher 
efficiency novel QD photovoltaic devices.
134
 Alternatively, the presented carbon coated 
QDs could also serve as excellent biological markers. 
Examining the influence of carbon coating on other types of nanoparticles, we 
have found no shift in absorption peak after coating carboxyl-PEG 3000 gold 
nanoparticles, however, the citrate stabilized gold nanoparticles experienced a red shift 
(Δλ= 5 nm). Since the smaller gold nanoparticles have large capping ligands (PEG3000), 
the carbon coating did not alter the surface dielectric medium as much as it did with the 
larger nanoparticle capped with a small ligand (citrate). Furthermore, in addition to the 
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SPR transverse peak at 553 nm, a broad peak (longitudinal peak) was observed (see Fig 
3.3) due to aggregation which causes a phenomenon called surface plasmon coupling in 
the near infrared region.
135,136
 As for the small gold nanoparticles, the PEG offered 
excellent stability even through the coating process, since there was no evidence of a 
longitudinal peak to infer any aggregation. 
X-ray diffraction patterns showed that the QDs exhibited a zinc blende structure 
and, after coating, prominent peaks were present due to the carbon. It is worth noting that 
the carbon-coated CdSe exhibited similar peaks to carbon nanoparticles. However, the 
diffraction patterns were different. Furthermore, the carbon-coated CdSe diffraction 
pattern is different from previously reported patterns of semi-crystalline or amorphous 
carbon nanoparticles,
137,138
 indicating that a new category of carbon nanomaterials could 
be present on the surface. 
Morphological characterization with TEM complemented the XRD data, showing 
a gray halo around the nanoparticles (QDs and gold) after coating with carbon. 
Furthermore, the size of the nanoparticles increased after coating; however, this coating 
did not diminish their optical properties. 
The above characterization results rule out the possibility of forming a mixture of 
carbon nanoparticles and QDs. Thus far, no one has reported the proposed synthetic 
strategy for carbon coating nanoparticles. 
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III.5 Conclusion 
In conclusion, the work presented here demonstrated a simple synthesis technique 
to carbon coat nanoparticles, more specifically, QDs. We foresee, future application of 
these carbon-coated QDs in diagnostics since the carbon coating can minimize 
cytotoxicity and enhance their brightness. In addition, we will examine the possibility of 
reducing other sugars to assess their potential in enhancing QDs intracellular journey.
1
  
                                                          
1
 This chapter is a reworked version of a published journal with reference Vance, S.A., Zeidan, E., Williams, 
L., Starobin, J., Sandros, M. AN EASY METHOD TO SYNTHESIZE CARBON-COATED QUANTUM DOTS. Nano 
LIFE 03 (01):1340006.2013. 
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CHAPTER IV 
ZEPTOMOLE DETECTION OF C-REACTIVE PROTEIN IN SERUM BY A 
NANOPARTICLE AMPLIFIED SURFACE PLASMON RESONANCE IMAGING 
APTASENSOR 
 
IV.1 Introduction 
An ultrasensitive platform with simultaneous fast profiling of multiple low 
abundance protein biomarkers from blood samples has the potential to provide a more 
comprehensive and accurate diagnosis/prognosis of different types of human diseases, 
including cancer, cardiovascular and neurological disorders. More importantly, a 
diagnostic biomarker should be able to highlight the early onset of a disease prior to the 
appearance of clinical symptoms to ensure a greater therapeutic efficacy.  Based on these 
prerequisites, the detection platform should have extremely high sensitivity (below 
pg/ml), as biomarker levels in biological fluids are extremely low conventional platforms 
are unable to provide such sensitivity in combination with multiplexing. ELISA is a 
commonly used technique for biomarker detection. It provides good sensitivity (pg/ml or 
femtomolar range), excellent specificity, and low coefficient of variation (2–5%)
139
. 
However, the optimization of these assays is labor intensive, requires large amounts of 
sample in development and use, and can only target a single protein per assay.  In 
addition, antibodies in ELISA present practical limitations such as low stability and high 
production cost. An alternative recognition probe to antibodies are synthetic single 
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stranded DNA/RNA aptamers which offer a large degree of specificity, high affinity, 
easy-to-perform modification, low cost and a rapid turnaround for production. Recently, 
aptamer-based biosensors exploiting detection by means of electrochemical
140
, optical
141
 
and mass-sensitive transducers
97,142
 have been developed. Of these assay formats, surface 
plasmon resonance imaging (SPRi) is the most advanced label-free optical/mass-sensitive 
technology for detecting biomolecular interactions in situ and in real time with high 
throughput. As stated earlier in section 1 SPRi is an optical technique that monitors 
refractive index changes at the metal/dielectric media interface. A high refractive index 
prism coated with a thin layer of gold (50 nm) couples the incident light (p-polarized) to 
the propagating surface plasmons at a specific angle and wavelength.
143
 Any perturbation 
to the sensor surface modifies the resonance conditions causing intensity variations of the 
reflected light at a fixed angle. The reflected light is then intercepted by a CCD camera 
allowing for the visualization of multiple interactions simultaneously on the sensor chip 
in real time together with the relative sensorgram.  The kinetic sensorgram plots the 
percent change in reflectivity versus time. There have been significant advancements in 
SPR-based biosensors in the last two decades, however, measuring ultra-low levels (sub-
ng/ml) of biomarkers in bodily fluids still remains a challenge.  To this end, a number of 
amplification techniques combining proteomics
144
 and genomics
145-147
 with nanomaterials 
have been proposed to increase the signal, or optical contrast, generated by the binding 
event in SPR.  For example, one strategy involves utilizing a sandwich-immunoassay 
type complex through the inclusion of gold nanoparticles in the sensing layer to detect 
biomarkers in serum
148
 and plasma
149
 with a detection limit range between 0.1–2.3 ng/ml.  
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Figure 4.1.  SPRi Comparison of Conventional and Microwave Assisted Surface 
Functionalization. Binding of CRP to sensor chip using conventional or microwave-
assisted surface functionalization. A plot comparsion of the SPRi kinetic signal after the 
injection of CRP (2 mg/ml) in buffer (10 mM Tris, 15 mM NaCl, 2 mM CaCl2 pH 7.4) 
onto a gold-coated prism that has been coated with Cystamine/Glutaraldehyde in the (a) 
absence and (b) the presence of microwave-assisted irradiation and followed by the 
functionalization of aminated CRP-specific and control aptamer. Both surfaces were 
blocked with BSA prior to injection of CRP. (c) A comparison of the equilibrium 
dissociation constant (KD) between microwave and conventional treated surface to the 
binding response of CRP. 
 
 
The SPR signal amplification is attributed to the coupling of localized surface plasmon 
resonance with SPR and a mass loading effect.
150
 Other strategies take advantage of the 
coupling of fluorescent probes such as QDs to metallic surfaces.
151,107,152
 Plasmonic field 
effects are known to improve the emission from fluorescent probes by several fold to 
produce highly directional and polarized emissions
153
. Moreover, the refractive index 
near the plasmonic surface is modified because of the presence of the fluorescent probes, 
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thus affecting the excitation and propagation of the plasmon wave.
154,155
 Recently, we 
have reported that the integration of near-infrared (NIR) QDs with SPRi enhanced the 
LOD
107
 due to a mass loading effect and spontaneous emission coupling with propagating 
surface plasmons. 
The detection of C-reactive protein (CRP) at 5 fg/ml (43 aM and/or 7 zeptomole) 
level in spiked human serum was made possible by implementing an ultrasensitive SPRi-
based nano-aptasensor. This ultrasensitive system was engineered through the unique 
integration and combination of the SPRi platform with microwave-assisted surface 
chemistry, aptamer technology and NIR QDs, to create a clinically relevant biosensor. 
CRP is a general inflammatory biomarker and useful in diagnosing inflammatory 
responses in cancer
156
, cardiovascular diseases
157
 and neurological disorders.
158
 In this 
study, CRP was simply employed as a model biomarker. To accurately diagnose most 
human diseases, panels of biomarkers need to be profiled simultaneously at real time with 
high sensitivity.  
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Figure 4.2. SPRi Comparison of PEG and BSA Blocking.  CRP binding to sensor chip 
blocked with BSA or PEG-SH. A plot comparison of the SPRi kinetic signal after the 
injection of CRP(2 mg/ml)in buffer (10 mM Tris, 15 mM NaCl, 2 mM CaCl2 pH 7.4) 
onto a gold-coated prism that has been functionalized with biotinylated CRP-specific and 
control aptamer followed by blocking with (a) BSA and (b) PEG-SH. (c) A comparison 
of the equilibrium dissociation constant (KD) between BSA and PEG-SH treated surface 
to the binding response of CRP. 
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Figure 4.3. Schematic of Sandwich Assay in Serum.  Illustration of the sandwich protocol 
implemented for the detection of CRP in biological fluid. The gold-coated prism is 
prefunctionalized with aptamers specific to CRP and control aptamers followed by the (a) 
direct detection of CRP(fg/ml) spiked in human serum and the(b) sandwich based assay 
using CRP-Specific_aptamer-coated QDs for SPRi signal amplification. Direct detection 
of CRP (fg/ml) does not generate a quantifiable sensor response as depicted with no 
change in the angle of reflectivity, however, with sandwich assay the NanoEnhancers 
induce a change in the reflectivity. 
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Due to the innate capabilities of the SPRi instrument for multiplexing and the proposed 
nano-aptasensor attomolar sensitivity, one can foresee the potential of extending this 
proposed platform to detect in real-time proteinaceous and non-proteinaceous molecules 
found in blood, urine, cerebrospinal fluid and other specimens that are indicative and 
even predictive of disease onset and progression. 
IV.2 Methods 
IV.2.1 Chemicals and reagents  
Cystamine dihydrochloride(Cys), glutaraldehyde solution 25% (Glu), phosphate 
buffered saline (PBS), poly(ethylene glycol) methyl ether thiol (PEG-SH), bovine serum 
albumin (BSA), extravidin were purchased from SigmaAldrich(St. Louis, MO, U.S.A.). 
Calcium chloride anhydrous (CaCl2), sodium chloride (NaCl), tris(hydroxymethyl) 
aminomethane (Tris) base for molecular biology and ethanol were all purchased from 
Fischer Scientific. Nanostrip™ was purchased from Cyantek Inc. Biotinylated 
CRP_specific Aptamer was purchased from OTC Biotech. Biotinylated control aptamer 
with the following sequence 59-GGGCCTCCGGT -TCATGCCGC-39 was purchased 
from Integrated DNA technologies. QDot 800 streptavidin conjugate was purchased from 
Life Technologies. 
IV.2.2 SPRi gold chip cleaning 
The gold-coated prism (Horiba Scientific, France) was sonicated in water for 30 
minutes at 50 ºC and then rinsed with ethanol and dried in the oven (60 ºC). To remove 
any organic contaminants, the gold-coated prism was then immersed in Nanostrip™ and 
then heated to 50 ºC under sonication for 90 minutes. The solution was then allowed to 
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cool to room temperature and then the prism was removed and rinsed with water to 
remove excess Nanostrip followed by sonication in water (50 ºC) for 30 minutes. The 
prism was then given a final wash with ethanol and dried with nitrogen. Finally, the 
prism was then placed into a UV Ozone Cleaner (ProCleaner TM Plus from Bioforce 
Nanosciences) for 20 minutes. If it is not noted below after the formation of each layer, 
the biochip was excessively rinsed with water and then dried with nitrogen. 
IV.2.3 Conventional surface chemistry 
To bind biotin-labeled aptamers onto the gold surface, we used 
Cystamine/Glutaraldehyde/Extravidin surface chemistry. The biochip was immersed in 
25 mM cystamine in 90% ethanol for 2 hrs and washed with ethanol. Afterwards, a 
second layer was formed by dipping the chip in a 2.5% solution of glutaraldehyde for 1 
hr. Finally, extravidin (0.2 mg/ml diluted in PBS, pH 7.4) was deposited on the chip and 
incubated for one hour in a humid environment (75% humidity) and rinsed with water 
followed by drying with nitrogen. Biotin-labeled CRP and control aptamers (10 µM) 
suspended in 10% glycerol were spotted (300 mm) using a SPRi Arrayer (Horiba 
Scientific) onto the surface and left to incubate for 2 hours at a humidity of at least 75%. 
IV.2.4 Microwave-assisted surface functionalization 
A cleaned gold-coated chip was immersed in a solution of cystamine (25 mM in 
90% ethanol) and then microwave irradiated (50 watts,5 minutes, 50 ºC) using a CEM 
Discover Labmate. Afterwards, the prism was rinsed and soaked for 5 minutes in 90% 
ethanol. The second layer formation involved depositing the chip in a 2.5% 
glutaraldehyde solution and irradiated with the same microwave settings as described 
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with cystamine. A solution of extravidin (0.2 mg/ml diluted in PBS buffer, pH 7.4) was 
deposited on the chip surface. Spotting of the biotinylated aptamers was done in the same 
manner as described in the conventional surface functionalization section above. 
IV.2.5 SPRi measurements 
SPRi measurements were performed using SPRi Lab instrument equipped with an 
800 nm laser, CCD camera, peek flow cell, programmable syringe pump (Harvard 
Apparatus PHD 2000) and an injection loop of 150 ml (Horiba Scientific, France) placed 
in a Memmert Peltier-cooled incubator (model IPP 500, Wisconsin Oven Distributors, 
USA) for temperature stabilization. The entire prism surface was monitored during the 
experiments; spots with a diameter of 300 mm were chosen to determine total reflectance 
change that indicates a binding event occurrence. For each injection, 40 SPRi signals 
were collected; background subtracted automatically and averaged using ScrubberGen 
Software. Each kinetic curve corresponds to an average curve of 20 spots for CRP-
Specific Aptamer and 20 spots for the control. The reproducibility of each measurement 
was thus expressed as percent change in reflectivity on the 40 SPRi signals relative to 
each sample injected on four different biochips (n=4). Reflectance change was monitored 
at the angle that is determined to be the highest slope of the plasmon absorption. The 
kinetics analysis was performed by plotting percent change in reflectivity (%ΔR) against 
time to illustrate the binding events. The SPRi difference images taken by the CCD 
camera were collected at real time to monitor the reactions occurring on the surface of the 
chip. The binding event was observed as an increase in the reflected intensity, regarded as 
a bright spot, which is easily distinguishable from the background (black). The reported 
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curves are the average of 20 spots (with the blocked surface reflectance change 
subtracted from the signal), each experiment has been repeated four times. The difference 
images were then used to show the reflectivity change to further confirm that a binding 
event has occurred. To retain the pentameric structure of CRP, the running buffer 
contained calcium. Protein binding experiments were performed at a flow rate of 5 ul/min 
using a running buffer of 10 mM Tris, 15 or 250 mM NaCl (the former concentration was 
used in 1% serum experiment and the latter in 20% serum experiment), 2 mM CaCl2 at 
pH 7.4.The prism was then blocked with an injection of 10 mM PEG-SH or 1% BSA 
followed by a running buffer rinse. The SPRi was then calibrated by injecting a sample of 
the running buffer that has a 25 or 260 mM NaCl concentration instead of the normal 15 
or 250 mM. This injection causes an increase in reflectivity due to the change in the 
dielectric constant. A calibration factor for each plot was then calculated and used to 
adjust all of the plots to the same change in reflectivity. CRP in running buffer or spiked 
in 1% or 20% human serum was then injected.  For all sandwich assays, 10 nM of 
Streptavidin Qdot 800™ was reacted with biotinylated CRP_Specific Aptamer 
(NanoEnhancers) for 30 minutes prior to injection. The NanoEnhancers were diluted with 
running buffer prior to injection into the SPRi system. Finally, %ΔR was computed by 
taking the difference between pre- and post- NanoEnhancers or protein injection (initial 
and final buffer signals). The reported limit of detection (LOD) represents the minimum 
detectable target concentration for which the SPRi signal (%ΔR) was at least three times 
higher than that of the control. Equilibrium dissociation constants (KD) were calculated 
using the ScrubberGen software. 
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IV.3 Results 
IV.3.1 Microwave-assisted surface functionalization 
In general, for a SPRi biosensor, the functionalization of chemical linkers on the 
surface of the gold-coated chip serves to provide means of attaching the capture probe. 
Conventional immobilization procedures using Cystamine/Glutaraldehyde (Cys/Glu) 
layers requires over 3 hours prior to introduction of the capture probe. In this study, we 
compared conventional methods with microwave-assisted surface functionalization of 
Cys/Glu to assess their influence on the binding interaction between the capture and 
target probe. In all SPRi experiments, the change in reflectivity (%ΔR) was calculated by 
taking the difference between the initial and final buffer signals. As Fig 4.1 shows the 
microwave treated chip had a significantly larger signal change (% Reflectance, 2 fold 
increase) after injection of CRP (a model biomarker) than the chip that was prepared 
through the conventional method. The calculated equilibrium dissociation constant (KD, 
Fig 4.1c) of the CRP aptamer decreased two order of magnitudes resulting in a stronger 
binding interaction. Microwave-assisted surface functionalization not only improved the 
detection and binding strength of CRP using SPRi but also decreased the 
functionalization procedure from several hours to minutes. 
IV.3.2 Blocking agent influence and optimization 
In addition to the immobilization of a chemical linker directly onto the gold 
surface for subsequent attachment of probes, the overall goal is to engineer a support 
construct that provides large degree of accessibility to the target probe while retaining 
good stability and minimizing capture probe detachment and non-specific binding.  
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Extravidin was selected as the direct chemical linker to the capture probe in order to take 
advantage of its strong binding affinity to biotinylated probes, as well as its superior anti-
fouling properties against human serum proteins. After the formation of the Cys/Glu 
layer, the gold surface was blocked with chemicals to prevent any non-specific 
adsorption from serum proteins. To this end, we compared two commonly used blocking 
agents, BSA and poly(ethylene glycol) methyl ether thiol (PEG-SH). After direct binding 
of the capture probe (biotinylated CRP_Specific Aptamer) to an extravidin coated 
surface, followed by injection of CRP in Tris buffer, the PEG-SH had a greater SPRi 
response than BSA (Fig 4.2a–b). 
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Figure 4.4. Amplified Detection of 500 pg/ml CRP in Spiked Serum.  (a) Binding of 
NanoEnhancers (CRP_specific_Aptamer-QDs) after the injection of PEG-SH and CRP 
(500 pg/ml) spiked in human serum to Cys/Glu/extravidin/Aptamer surface coated gold 
chip and (b) SPRi difference images showing the binding of NanoEnhancers to CRP 
(left) and control (right). (c) A plot profile of the SPRi difference image revealing 
intensity values to the area indicated by the yellow line in b and shows the change in 
contrast due to the binding of NanoEnhancers in spots functionalized with CRP_Specific 
aptamer (left, A1–A5), control aptamer (right, C1–C5). The middle region of the line is 
the background. 
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When comparing their binding affinity, both exhibited similar values (Fig 4.2c), 
however, PEG-SH provided better accessibility for CRP to bind to the immobilized 
aptamer. 
IV.3.3 Determination of SPRi limit of detection for CRP in human serum 
Our final construct for the detection platform involved using a microwave-
assisted Cys/Glu coated gold chip that was immobilized with extravidin for direct 
attachment of the capture probe (biotinylate CRP_specific aptamer). The sensor chip was 
further blocked by injecting PEG-SH inside the instrument. Following the injection of a 
solution of CRP spiked in 1% human serum, an intense SPR signal response with a weak 
association was observed and an abrupt signal drop was observed shortly after. (Fig 4.6) 
The intense SPR response is due to the high refractive index difference between the Tris 
buffer and the serum. In addition, it could be attributed to weak non-specific interaction 
of serum proteins. Therefore, using the direct detection method for CRP spiked in human 
serum is challenging, as one cannot precisely quantify the amount of CRP (Fig 4.3a).  
To overcome this challenge, we designed a sandwich based assay that uses 
CRP_specific Aptamer coated NIR QDs (NanoEnhancers) to amplify the signal for the 
SPRi sensor (Fig 4.3b). As shown in Fig 4a, the introduction of the NanoEnhancers to a 
pre-injected solution of CRP (500 ng/ml) in human serum resulted in 17.85 ± 0.54 
(%ΔR), while the control sample had minimal change (%ΔR = 1.74 ± 0.22). In addition, 
a difference image (Fig 4.4b) was recorded to correlate the binding kinetics after injection 
of NanoEnhancers. The spots that have been pre-functionalized with CRP_specific 
Aptamers (left) are intensely illuminated as opposed to control aptamers spots (right). 
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The correlation between the binding kinetics and the difference images (plot profile) 
helps further validate the binding interaction between aptamer-CRP and NanoEnhancers.  
The formation of the NanoEnhancers-CRP complex (KD = 169 pM ± 1.6) resulted in 
higher affinity in comparison to the formation of Aptamer-CRP complex (KD = 5.76 nM 
± 1.01). Furthermore, we examined the influence of BSA in the sandwich based assay 
format and found that there was no signal enhancement after the addition of the 
NanoEnhancers (Fig 4.7). 
To further investigate the reliability of the biosensor in distinguishing different 
amounts of CRP present in human serum, we assessed the sensor performance with a 
range of CRP concentrations. A decrease in SPRi signal was observed as the amount of 
CRP spiked in human serum was lowered (Fig 4.5a). To further assess the robustness of 
our platform, serum concentration was increased from 1%to 20%. A complementary 
response was observed after the injection of 500 pg/ml of CRP in 20% serum (Fig 4.8) in 
comparison to the corresponding experiment performed in 1% serum (Fig 4.5a). 
Examining the extended range of the concentration gradient curve in Figure 4.5b, the 
detection platform exhibited a biphasic response that can be interpreted as the result of 
two binding sites with different affinities. The biphasic response is common with SPR 
sensors when proteins multimerize. In our case, CRP in the presence of calcium, 
conforms to a pentameric structure,
159
 as a result, two binding sites with different 
affinities are observed. However, at the lower concentration range, the detection platform 
exhibited a linear trend in the region from 5 fg/ml to 5000 fg/ml (Fig 4.9). The LOD was 
validated to be 5 fg/ml, this in agreement with the LOD having a 3-fold higher response 
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than the control, when taken into consideration the error due to standard deviation (inset, 
Fig 4.5b). 
IV.4 Discussion 
Microwave assisted chip-surface modification offers fast turnaround time and a 
stronger support structure for the capture probe. The acceleration in reaction time with 
microwave irradiation
160
, in comparison to conventional methods, is due to the 
conversion of electromagnetic energy into heat, rendering a robust SPRi sensor with 
better sensitivity and avidity. In addition, the aptamer binding affinity was comparable to 
CRP antibodies.
161
 We have found that the type of blocking agent used greatly influences 
the capture probe interaction with analyte, as well as with the NanoEnhancers.  
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Figure 4.5. Detection of CRP in Spiked Serum with PEG Blocking.  A sandwich assay 
using NanoEnhancers for the detection of CRP spiked in human serum.(a)Normalized 
SPRi kinetic plot representation of CRP_specific_Aptamer-QDs-amplified signal for 
human serum samples spiked with different concentrations of CRP. A vertical dashed 
line (grey) represents the injection point of the running buffer. (b) A concentration 
gradient curve representing the binding of NanoEnhancers (CRP_specific_Aptamer-QDs) 
after the injection of various amounts of CRP spiked in human serum to the sensor 
surface that has been prefunctionalized with biotinylated CRP-specific (black) and 
random aptamer as a control (red). The inset figure depicts the percent change in 
reflectivity (%ΔR) after introduction of NanoEnhancers for 5 fg/ml, 50 fg/ml and 5000 
fg/ml. 
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 For potential clinical applications of SPRi, much effort was spent in optimizing the 
surface chemistry of the sensor; the combination of PEG-SH/ Extravidin
162
 and 
microwave-assisted functionalization with Cys/Glu was found to significantly improve 
the efficiency and performance of the biosensor. 
There are several challenges in directly detecting biomarkers in human serum 
using the SPRi platform, because the direct response from the binding of biomarker to the 
sensor surface can be masked by non-specific interactions from sera proteins (higher in 
concentration than desired biomarker), changes in the refractive index of injected solution 
from the running buffer, and analyte concentration falling below the LOD of the 
instrument. To overcome these obstacles, we employed a sandwich-amplification strategy 
using NanoEnhancers that allowed us to detect CRP (model biomarker) in human serum 
at a LOD of 43 attomolar (5 fg/ml). Many previously reported strategies utilize gold 
nanoparticles in complex samples
148,149,163
 or buffered conditions
154,164,165
 to amplify the 
SPR signal for detection of biomolecules; however, the level of sensitivity attained with 
our platform is by far superior. Previously, it was reported that the use of NIR QDs for 
signal amplification of PSA using antibodies as capture probes and PEG-COOH/PEG-
OH as the surface coating and attained a LOD of 2.5 ng/ml.  We employed aptamers as 
opposed to antibodies
107
 to serve as the capture probe. We have found that by using 
aptamers in a sandwich assay, sensitivity of the sensor is improved, as observed by Kim 
and co-workers
97
. We attribute this increase in sensitivity to a decrease in the separation 
distance between the QDs and the sensor surface, as a result of the aptamer folding from 
a single stranded DNA to tertiary structure after binding to analyte, or perhaps due to 
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differences in length between aptamer and antibody. In addition, we observed that the 
aptamers conjugated on quantum dots experienced a one order of magnitude 
improvement in affinity compared to its parent aptamer (immobilized capture molecule). 
This enhancement could be a result of several aptamers and CRP binding
166
. Increasing 
the serum concentration from 1% to 20% did not affect the percent change in reflectivity 
after the addition of NanoEnhancers. However, to minimize non-specific binding from 
excess proteins present in the sample, the salt concentration in the running buffer was 
increased from 15 mM to 250 mM. The exact mechanism behind NIR QDs SPRi signal 
enhancement is still not very well understood, however, a few hypotheses could be 
presented here. One hypothesis is that a mass loading effect and the other suggests NIR 
fluorophores will couple the scatter light more strongly onto gold film nanostructures
167
. 
Nanometer thick gold film have a stronger absorption
168
 in the NIR as opposed to the 
visible range. As highlighted in our previous work,
107
 the visible red emitting quantum 
dots (550–650 nm) had a lower SPR amplification signal than the NIR quantum dots (800 
nm). Furthermore, Wei et al
155
 refers to a bidirectional relationship between QDs and SPs 
on a silver nanowire, where energy is transferred from propagating SPs to the excitons 
and the excited QDs prompt the generation of propagating surface plasmons in the silver 
nanowires. All above mentioned work suggest that metallic film-QD heterostructures 
experience unique interactions that we are still in the process of exploring greatly to 
further understand their principal mechanism and applications. Finally, this work 
highlights and establishes the ability of SPRi sensors to achieve zeptomole sensitivity in 
biological fluids as a result of combining NIR QDs with smart surface engineering. 
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IV.5 Supplementary   
 
 
Figure 4.6. SPRi Signal of Spiked Serum Injection. An SPRi kinetic plot after the 
injection of PEG-SH followed by CRP (500 ng/ml) spiked in human serum to a pre-
functionalized chip with Cys/Glu/Extravidin/biotinylated CRP-specific Aptamer and 
control aptamer. 
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Figure 4.7. Amplified Detection of CRP with BSA Blocking. Introduction of 
nanoEnhancers (CRP_specific_Aptamer-QDs) after the injection of BSA followed by 
CRP (500 ng/ml) spiked in human serum to Cys/Glu/extravidin/Aptamer surface coated 
gold chip. 
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Figure 4.8. Amplified Detection of CRP in 20 % Serum.  Binding of NanoEnhancers 
(CRP_specific_Aptamer-QDs) after the injection of PEG-SH and CRP (500 pg/ml) 
spiked in human serum to Cys/Glu/extravidin/Aptamer surface coated gold chip. A 
vertical dashed line (grey) represents injection point of running buffer. 
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Figure 4.9. Calibration Curve for CRP Detection. Linearity of SPRi response against the 
CRP concentration spiked in human serum after the injection of NanoEnhancers for 
signal amplification. 
2
 
 
  
                                                          
2 This chapter is a reworked version of a published journal with reference Vance, S.A., 
and Sandros, M.G. Zeptomole Detection of C-Reactive Protein in Serum by a 
Nanoparticle Amplified Surface Plasmon Resonance Imaging Aptasensor. Sci. Rep. 
4.2014. 
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CHAPTER V  
COMPARATIVE ANALYSIS OF HUMAN GROWTH HORMONE IN SERUM 
USING SPRI, NANO-SPRI AND ELISA ASSAYS 
 
V.1 Introduction 
 
Human growth hormone (hGH) is a 191 amino acid peptide (22 kD) produced by 
the pituitary gland and directly released into the bloodstream. Interactions between the 
hypothalamic peptide growth hormone-releasing hormone (GHRH) and somatotropin 
induce pulsatile secretions of hGH. As a result, levels of hGH vary from highs in the 50-
100 ng/ml to lows in the 0.03 ng/ml range.
169
 Deficiency or excess of hGH in the body 
can provoke a wide range of abnormal physiological symptoms. For example, excess 
levels of hGH can lead to gigantism
170
 and diabetes.
171
 Depleted levels of hGH cause low 
blood sugar in newborns, and weak bone density and depression in adults.
172
  
The administration of the recombinant form of hGH (rhGH) improves lean 
muscle mass while reducing body fat. As such, this substance became the drug of choice 
for professional and amateur athletes as it improves physical strength that confers an 
advantage in competitive sports. rhGH is banned by the World Anti-Doping Agency 
(WADA) and much effort has been focused on developing tests that can detect its 
presence or anabolic effect in the human body.
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Enzyme-linked immunosorbent assay (ELISA) has been the preferred method for 
the determination of hGH in whole blood.
173
 Although ELISA is a reliable technique 
offering good sensitivity and selectivity, it is relatively time- and labor-intensive. In 
addition, ELISA relies on the indirect detection of hGH by employing enzymatic tags. In 
contrast, surface plasmon resonance (SPR) permits detection of hGH directly without the 
use of labels in real time. The detection principle behind SPR involves a sensing surface 
consisting of a prism that is coated with a thin metal layer (gold or silver); when a 
monochromatic polarized light interacts with the metal surface, “surface plasmons” are 
generated. The binding of an analyte to a surface receptor immobilized on the metal 
surface perturbs the resonance conditions resulting in a shifted resonance dip, which can 
then be correlated to the analyte concentration. SPR-based biosensors are now 
commercially available that offer a real-time, label free technique to monitor 
biomolecular binding events and biochemical reactions.
174,175,143
 More recently, SPRi was 
developed in response to the need for multiplexing (i.e. monitoring multiple binding 
events simultaneously), which was not possible in classical SPR biosensors. Thus, SPRi 
has emerged as a tool to monitor several binding events simultaneously. Current SPRi 
systems are based on microscopic imaging of a surface which is excited with light at a 
specific angle and wavelength.
143
 The image is then captured onto a CCD array.  
To date, there have been a few SPR-based assays developed to detect hGH.
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One particular strategy, known as the isoform method
180
, relies on the detection of the 
ratio of 22 kD hGH to total hGH, as non-22-kD endogenous levels drop after exogenous 
rhGH administration. Recently, de Juan-Franco et al.
176
 reported on the development of a 
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SPR-based immunosensor for the selective detection of the 22 kD and 20 kD hGH 
isoforms in human serum samples. Monoclonal antibodies specific to each isoform were 
immobilized directly on the gold sensor permitting the measurement of both isoforms 
simultaneously in a single injection with a limit of detection at 0.9 ng/ml. Alternatively, 
SPR has been used to screen antibodies with high specificity to hGH.
178
   If the 
concentration of target analyte falls below the SPRi system’s limit of detection (< 1 nM), 
one has to resort to amplifying the SPRi signal via the utilization of nanoparticles (Nano-
SPRi). Such SPR-based amplification has been well documented in the 
literature
107,181,148,149
 for various types of analyte and surfaces.  
In this work, the analytical potential of SPRi and Nano-SPRi based biosensors 
was examined, particularly for the detection of rhGH in spiked human serum, and 
comparison of its detection capability directly to ELISA. The following parameters will 
be reviewed and considered: detection time, sensitivity, kinetic profile, reproducibility 
and specificity. 
V.2 Methods  
V.2.1 Preparation of solutions and protein samples for SPRi 
These solution were prepared a low salt phosphate buffered saline (PBS) solution 
(10 mM phosphate, 150 mM sodium chloride and pH 7.4), a high salt PBS solution (10 
mM phosphate, 750 mM sodium chloride, and pH 7.4) and a 10 mM sodium acetate 
solution.  Stocks of 5 mg/ml bovine serum albumin, 1 ug/ml recombinant human growth 
hormone in low salt PBS solution were then prepared.  Stock solutions of anti-rhGH and 
negative control antibody at a 100 ug/ml concentration were prepared in 10% tween 20. 
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V.2.2 Prepare SPRi chip for antibody array 
The gold prism was cleaned by sonication in 120 ml of stabilized piranha solution 
for 90 minutes at 50 C and followed by rinsing and sonication with water for 5 minutes. 
The chip was then rinsed with ethanol and dry with nitrogen stream.  The chip was then 
placed in an UV/Ozone chamber for 30 minutes to remove any organic contaminants.  A 
solution of 150 mg 11-mercapoundecanoic acid in 20 ml ethanol was placed into a test 
tube containing a stir bar and tube cap.  The gold chip was then placed into the test tube 
and the tube will be placed into a CEM microwave and irradiated at 50 W and 50 ºC for 5 
minutes.  Any unreacted chemicals were rinsed away by rinsing and soaking the chip in 
ethanol for 5 minutes followed by rinsing and soaking in water.  A solution of 150 mg of 
EDC in 20 ml water was mixed in a test tube.   The gold chip was placed into the tube 
and irradiated in the microwave as stated above.  The unreacted EDC was removed by 
rinsing and soaking in water for 5 minutes.  A solution of 150 mg NHS in 20 ml water 
was mixed and reacted with the surface and the unreacted material washed off as with the 
EDC.  In order to prevent non-specific binding in further steps a solution of 250 µM 
thiolated polyethylene glycol in 20 ml of water was microwaved onto the surface to fill in 
any holes left in the surface during the functionalization step.  A solution of 15 µg/ml 
anti-rhGH and negative control antibody was prepared and was spotted onto the chip in a 
4 by 7 array using the Xact II arrayer.  Antibodies were allowed to bind to the surface for 
2 hours under a humid atmosphere of 75% or higher.  Residual unreacted material was 
then removed by rinsing and soaking in water for 5 minutes and the chip was then dried 
under nitrogen stream and placed into the SPRi instrument. 
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V.2.3 SPRi Experiment Setup and blocking 
The instrument was initialized and the save directory chosen. The syringe pump 
was started at a flow rate of 1 ml/min and the chip was inserted.  Water was then flowed 
across the chip until all bubbles are removed.  The buffer was then changed to low salt 
PBS. Five milliliters of the buffer was injected into the instrument.  The flow rate was 
slowed down to 20 µl/min for 20 minutes to allow for equilibration.  The real time 
display was then turned off and the instrument scanned across all of the possible display 
angles such that the user could select which image had the best contrast, allowing for 
easy detection of immobilized antibodies.  The spots will be selected and spots classified 
as being anti-rhGH, negative control, or background. The instrument then made traces of 
both the absorption of the plasmon curves and the first derivative.  The highest value on 
the first derivative graph allowing for highest sensitivity of the instrument.  The 
experiment started in calibration mode where the system was allowed to stabilize until 
there was minimal change in signal (less than 0.15 drop in signal over 5 minutes).  A 
solution of 100 µg/ml BSA was injected onto the surface to and allowed to chemically 
bind to the gold surface by reacting with the EDC/NHS activated surface. The surface 
was then washed by rinsing with 10 mM sodium acetate and high salt PBS.  The 
EDC/NHS activated surface was deactivated by injection of 1 mM ethanolamine and 
washed with 10 mM sodium acetate.  The buffer was changed to low salt PBS spiked 
with 50 µg/ml BSA to allow for non-specific binding of BSA to the surface.  Five 
milliliters of buffer was allowed to flow over the surface at a flow rate of 250 µl/min.  
The flow rate was then slowed down to 5 µl/min and allowed to stabilize for 20 minutes. 
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V.2.4 SPRi detection of human growth hormone 
A solution of rhGH (30,000 pg/ml; 250 pg/ml; 25 pg/ml; 2.5 pg/ml and 0.25 
pg/ml) was diluted in low salt PBS containing 10% serum and 1 mg/ml BSA.  Also a 
solution of 2:1 biotin-labeled anti-rhGH detection antibody and streptavidin-labeled QDs 
will be incubated for 30 min to allow for effective coupling.  The hGH solution was 
injected across the surface and the signal will spike as a result of the serum proteins and 
BSA in the solution, masking the hGH binding.  The signal start edto drop as the non-
specifically bound proteins washed off the surface and a solution of low salt PBS spiked 
with 450 mM sodium chloride was injected to destabilize more non-specifically bound 
proteins. A diluted solution of anti-rhGH detection antibodies and quantum dots at a 
concentration of 10 nM (2:1) with running buffer (PBS with 50 µg/ml BSA) and inject 
into the flow cell. 
V.2.5 SPRi Data Analysis 
The data was imported into a data analysis program. The SPRi signal (% 
Reflectivity) was plotted versus time (s) and the difference between the anti-rhGH and 
negative control antibody spots was determined after the high salt wash. 
V.2.6 ELISA protocol (Day 1) 
Store all assay components included in the rhGH ELISA kit at 2-8 ºC. This 
includes the anti-rhGH antibody coated well plates, standards (0-5) in sheep serum, 
controls (1&2) in human serum, conjugate buffer, (200X) wash buffer, chromogen TMB 
(Tetramethylbenzidine) and stop reagent. The reagents were setup and the methods 
described in the commercial ELISA kit protocol were followed. The anti-rhGH antibody 
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coated 96-wells were allowed to warm to room temperature prior to opening the foil 
package. The desired number of 8-well strips was removed for the assay and the foil 
package containing the remaining wells were stored at 2-8 ºC.  Standards were prepared 
by reconstitution in 2 ml of distilled water for standard #0, in 1 ml of distilled water for 
standards (1-5), and in 1 ml of distilled water for the controls (1&2). Below is a table of 
the corresponding concentrations of the standards and controls (Table 5.1). 
 
Table 5.1. Concentrations of Standards and Controls Included in Commercial ELISA Kit. 
 
  
 
The samples consisting of the rhGH hormone in 10% human serum were prepared at 
concentrations shown in table 5.2. 
 
Table 5.2 Concentrations of the rhGH Samples Prepared in 10% Serum. 
 
 
 
Standards Concentration (ng/ml)
0 0
1 0.17
2 0.94
3 2.63
4 10.4
5 26.9
Control #1 1.22 ± 0.33 ng/ml
Control #2 4.97 ± 1.25 ng/ml
Sample Concentration (ng/ml)
1 0.025
2 0.2
3 0.5
4 2.5
5 10
6 30
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Fifty microliters of each standard, control and sample were added to each well (in 
triplicates). The wells containing the standards, controls, and rhGH samples were 
incubated overnight at 4 ºC under gentle shaking. 
V.2.7 ELISA protocol (Day 2) 
The plate from the shaker was removed and allowed to warm to room temperature 
(15-20 min) prior to proceeding with the assay. The Anti-rhGH-HRP, conjugate buffer, 
wash buffer (200x), chromogen TMB, and stop reagent are removed from the refrigerator 
and allowed to warm to room temperature. The Anti-rhGH-HRP 40x was diluted with the 
conjugate buffer and the wash buffer is prepared by diluting 200x with distilled water.  
The anti-rhGH-HRP was added to each well (50 µl) and allowed bind to hGH in the well 
and the wells were sealed and incubated at room temperature for 30 minutes while gently 
shaking. The solution was decanted from the wells and the plate was inverted and tapped 
dry onto an absorbent tissue. Two hundred microliters of wash buffer was added into 
each well. The wash solution was decanted and tapped dry onto an absorbent tissue. The 
addition and decanting of the wash solution was repeated three times.  One hundred 
microliters of Chromogen is added into each well and was incubate for 30 minutes at 
room temperature in the dark while gently shaking. The solution turned from colorless to 
blue. A stop reagent was then added into each well causing the solution to turn from blue 
to yellow.  Immediately, the absorbance of each well was read at 450 nm using a 
microplate reader. The optical density of the rhGH in 10 % serum samples and 6 
standards was then plotted versus the concentration of each sample. 
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V.3 Results 
The performance of SPRi and Nano-SPRi (SPRi employing the NanoEnhancers) 
was compared with ELISA for the detection of rhGH in a complex environment. The 
differences in the setup of these methods are described here briefly. For SPRi (direct 
detection, Figure 5.1), the capture antibody is immobilized on the surface and then the 
sample is injected and binding of analyte to the sensor surface is measured directly in real 
time and label-free manner. However, with Nano-SPRi (Figure 5.1), after the analyte 
binds to the sensor surface, a consecutive injection is followed with quantum dots coated 
with detection antibodies to amplify the SPRi signal.  
 
 
Figure 5.1. Schematic of Direct and Amplified Detection of hGH in Spiked Serum.  
Ligands (rhGH or IgG specific antibodies) were immobilized in an array format on the 
SPRi biochip. Target protein (rhGh) spiked in human serum introduced to the sensor 
surface are directly detected (SPRi) and sequentially highlighted with NanoEnhancers 
(Nano-SPRi). 
 
 
As for ELISA, the multiwell plates arrive already pre-functionalized with capture 
antibody, when the sample is introduced, the analyte of interest will bind. A detection 
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antibody is introduced followed by substrate addition. The optical density is then 
measured at 450 nm. In this study, a commercial ELISA kit (Figure 5.2) was used to 
measure rhGH spiked in 10 % human serum.  
 
 
Figure 5.2. Schematic of ELISA Assay. rhGH protein (blue ovals) is introduced to wells 
that have been pre-functionalized with monoclonal antibodies (yellow) specific to rhGH. 
Non-specific interactions are eliminated by rinsing the wells with wash buffer followed 
by the introduction of a detection antibody prefunctionalized with horseradish peroxidase 
(HRP, purple). The solution will change in color after adding the substrate 
tetramethylbenzidine (TMB, gold). 
 
 
Figure 5.3 represents the titration curve of rhGH spiked in 10 % human serum and is 
plotted against the obtained OD at 450 nm. A good linear response was observed and the 
limit of detection was determined to be 1 ng/ml. The coefficient of variation (CV) was 
6.5 % suggesting good reproducibility. 
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Figure 5.3. ELISA Signal from Detection of hGH in Spiked Serum. Concentration of 
rhGH spiked in serum is plotted against the obtained OD at 450 nm. 
 
 
Next, the detection of rhGH spiked in human serum was assessed with SPRi. Direct 
detection of rhGH resulted with the corresponding concentration gradient curve (Figure 
5.4), each point represents the average value of the reflectivity difference calculated from 
three SPRi kinetic curves for each concentration. The limit of detection (LOD) was 
determined to be 3.61 ng/ml. The SPRi direct detection assay was highly reproducible as 
the CV of the assay was only 4.1 %. 
82 
 
 
Figure 5.4. SPRi Direct Detection of hGH in 10 % Serum. The resultant normalized SPRi 
kinetic plot after the injection of various amounts of hGH spiked in human serum 
followed by the injection of a high salt buffer (dashed vertical line) to remove non-
specific interactions . A concentration gradient curve representing the binding of various 
amounts of hGH spiked in human serum to the sensor surface that has been 
prefunctionalized with biotinylated hGH-specific-Antibody. 
 
 
To increase the sensitivity of the SPRi biosensor, NanoEnhancers (QDs pre-
functionalized with detection antibodies) are sequentially introduced to the sensor surface 
in order to highlight the presence of rhGH spiked in human serum. After background 
subtraction, the NanoEnhancers were able to amplify the biosensor response up to 7.9 %, 
however, with minimal signal change (Immunoglobulin G (IgG)-specific antibody,      
0.38 % change in reflectivity; Figure 5.5 on controlled regions of interest. Imaging of the 
sensor surface revealed that only regions of interest that have rhGH-specific antibodies 
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immobilized experience the largest contrast change corroborating directly with the kinetic 
sensorgram response.  
 
 
Figure 5.5. SPRi Amplified Detection of hGH in 10 % Serum. SPRi kinetic plot after the 
injection of rhGH (30 ng/ml) in buffer (10 mM PBS, 150 mM sodium chloride, pH= 7.4) 
onto a pre-functionalized chip with 11-mercaptoundecanoic acid / rhGH-specific 
antibody and control IgG-antibody then blocked with BSA followed by the addition of 
NanoEnhancers. 
 
 
To demonstrate the practicability of the Nano-SPRi biosensor, the measuring 
range of rhGH in crude samples was assessed. An extended working range from 30,000 
pg/ml to 0.25 pg/ml resulted as a response to the addition of NanoEnhancers (Figure 5.6). 
It is worth noting that each point on the titration curve is averaged from three 
independent experiments. Consequently, the lower limit of detection was calculated to be 
9.20 pg/ml and the coefficient of variation was 20 %.  
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Figure 5.6. Calibration Curve for the Amplified Detection of hGH. Normalized SPRi 
kinetic plot representation of hGH_specific_Anti-QDs-amplified signal for human serum 
samples spiked with different concentrations of hGH. A vertical dashed line (grey) 
represents the injection point of the running buffer. (b) A concentration gradient curve 
representing the binding of NanoEnhancers (hGH_specific_Anti-QDs) after the injection 
of various amounts of hGH spiked in human serum to the sensor surface that has been 
prefunctionalized with 11-mercaptoundecanoic acid /hGH-specific antibody. 
 
 
Next, the change that occurs in the SPR reflectivity curve as a function of the 
concentration was compared between the direct and the NanoEnhancer bioassay method 
(Figure 5.7). For the direct detection technique between 25 and 0.25 pg/ml, the signal 
started to plateau.  This is not surprising considering that these concentrations fall below 
the LOD of 3 ng/ml (Figure 5.7). Similarly, for the amplified technique, concentrations 
below the LOD of 9.2 pg/ml signal started to plateau and showed virtually no variation.  
85 
 
 
Figure 5.7. Direct and Amplified Detection of hGH in Spiked Serum. This bar graph 
depicts the percent change in reflectivity (%ΔR) after introduction of rhGH spiked in 
human serum (direct detection) followed by the injection of NanoEnhancers (amplified 
detection) for 30,000 pg/ml, 250 pg/ml, 25 pg/ml, 2.5 pg/ml and 0.25 pg/ml. 
 
 
Furthermore, the specificity of the Nano-SPRi biosensor was assessed. Insulin-
like growth factor-1 (IGF-1) spiked in human serum was injected as a control since hGH 
stimulates the secretion of IGF-1 through the growth hormone receptor on the hepatocyte 
membrane. After the injection of the IGF-1 in serum, the NanoEnhancers were 
sequentially injected and the SPR signal response did not show any specific binding 
(Figure 5.8). However, when rhGH spiked in serum sample was injected to the very same 
spot functionalized with rhGH antibody, signal enhancement was observed. In 
conclusion, the Nano-SPRi platform has demonstrated excellent specificity and 
selectivity for rhGH.  In addition to determining specificity of the rhGH to the specific 
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antibody, multiple negative controls were also tested as shown in Figure 5.9 which tested 
a rabbit IgG 2 and mouse IgG 2a spotted onto the surface.  Both antibodies performed 
similarly showing appropriate negative selection. 
 
 
Figure 5.8. SPRi Assessment of Selectivity for Amplification Method. The Nano-SPRi 
biosensor response after the injection of rhGH (black) and IGF-1 (red) in spiked serum. 
 
 
A correlation analysis was performed using the Pearson correlation coefficient to 
determine the correlation between the SPRi signal intensity and ELISA optical density 
values (Figure 5.9). A p-value < 0.01 was considered significant. As illustrated in this 
graph, there is a good correlation between the rhGH levels in spiked human serum 
measured by SPRi and ELISA. The r-value was 0.9263 for 9 different samples.  
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Figure 5.9. Negative Control Testing  
 
 
 
Figure 5.10. Correlation of SPRi and ELISA Detection of hGH.  The plot correlates 
Nano-SPRi signal intensity (y-axis) with ELISA optical density (x-axis) values. (Pearson 
correlation coefficient n=9, r=0.9263, p=0.00000183). 
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The equilibrium dissociation constant (KD) was determined using the graph pad 
software for ELISA. The calculated KD value was approximately 79 nM. The on (Ka) and 
off (Kd) rates could not be determined by ELISA. However, using the data analysis 
software, the direct detection method resulted with KD value of 23 pM using the 
molecular mass of 22 kD that corresponds to one rhGH molecule. The on and off rates 
were calculated to be 6.1 x10
7
 M
-1
s
-1
 and 1.33x10
-3
 s
-1
, respectively. This inherently 
translates that 0.13 % of the rhGH and antibody complexes decay per second. As for the 
amplified SPRi experiment, a stronger overall interaction was observed between 
NanoEnhancers and rhGH as the calculated binding affinity was determined to be 4.3 
pM. In addition, a stronger association rate was observed for NanoEnhancers and rhGH 
than capture antibody/rhGH, however the dissociation rate suggests that 0.26 % of 
NanoEnhancer/rhGH/Capture antibody decay per second.  
V.4 Discussion  
Irregular levels of hGH, a naturally occurring hormone, have been linked to 
numerous medical disorders that affect human growth and development. Moreover, 
exogenous administration of rhGH is commonly used by athletes, even though it is 
forbidden, as a doping agent to enhance their performance. Challenges in detecting rhGH 
misuse result from the difficulty in distinguishing exogenous hGH from endogenous 
form. As such, the current approved technique for detecting exogenous hGH relies on 
measuring the ratio of the 22 kD hGH isoform in relation to the 20 kD isoform. Since the 
isoform test demands for the measurement of multiple hGH isoforms simultaneously 
within a short period of time in a wide range of concentrations, therefore, we considered 
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the SPRi platform as a perfect match. In addition, endogenous hGH level fluctuate to a 
very low level (0.03 ng/ml) in the bloodstream therefore the detection system must be 
able to measure this range comfortably with high specificity. As a result, we also 
investigated in this study the potential of Nano-SPRi as a diagnostic tool for hGH and 
compared it directly with SPRi and the classical immunoassay ELISA.  
Based on results obtained from this study, the main advantage of the SPRi and Nano-
SPRi method is that rhGH concentrations can be measured in a quicker manner in 
comparison to the more conventional method ELISA. A standard duration for measuring 
rhGH levels in one sample with the direct detection method was one hour whereas the 
Nano-SPRi required two hours due to the additional steps in the process. Overall, with 
SPRi and Nano-SPRi experiments, before the injection of a sample, a calibration step is 
highly recommended. In addition, the injection of a crude sample like human serum 
results in some non-specific interactions as a result it is imperative to inject a high salt 
wash buffer to only reveal specific interactions. It is also worth noting that a wash step is 
absolutely necessary after the introduction of blocking molecules to the sensor surface, to 
remove unbound molecules. As for ELISA time requirements are far greater (~16-18 h) 
for the analysis of one sample. A longer incubation time is needed as the sensitivity of the 
assay is enhanced especially for this study, as the focus was to compare the lower limit of 
detection.  
The choice of surface chemistry will vary from one application to another and this 
could be realized as one of the limitation of the SPRi technique. In this study, a wide 
range and combination of chemical linkers and blocking molecules were assessed to 
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achieve the right combination in order to observe optimal binding efficiency of rhGH to 
the sensor surface. For example, in this study, the combination of BSA and PEG served 
well in minimizing non-specific interactions. However, in a previous study
181
, where the 
capture ligand was an aptamers, PEG alone served as the best blocking molecule. The 
variables that affect binding efficiency of analyte to ligand are also dependent on pH, 
buffer and temperature. Therefore, with any application, these variables need to be 
optimized. In addition, it is critical to determine the optimal spotting concentration of the 
ligand to the chip surface. A titration experiment with a range of concentrations of 
immobilized ligands is performed before initiating the study. As for ELISA, a crucial step 
in the procedure was to decant the wash buffer from wells by tapping the microplate as 
this ensured no residual liquid is leftover. Removing the buffer wash with a pipette was 
not sufficient as any residual liquid interfered with the signal reading of the target 
sample.  
In reference to sensitivity, ELISA (1 ng/ml) is comparable to SPRi (3.61 ng/ml) 
but nano-SPRi (9.20 pg/ml) improves sensitivity by three orders of magnitude, thereby 
enabling measurements at the lower biological levels of rhGH 0.03 ng/ml. As we 
previously reported,
182,107
 the signal enhancement imparted by the NanoEnhancers is 
attributed to a mass loading effect and the strong coupling that exists between NIR 
fluorophores and propagating surface plasmons for gold film nanostructures. Even 
though, Nano-SPRi adds an extra step to the procedure, this level of sensitivity can widen 
the applications of SPRi technology in various outlets. 
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SPRi provides scientists a full kinetic profile (KD, Ka and Kd) of antibody/rhGH 
interaction whereas ELISA can report only affinity values. The coefficient of variation 
(CV) was below 10 % for SPRi (4.1 %) and ELISA (6.5 %), suggesting good 
reproducibility. The ELISA and SPRi affinity values are different because the capture 
antibodies immobilized on the sensor chip are different from antibodies immobilized in 
the ELISA 96-well plate. As for Nano-SPRi a higher CV value (20 %) was observed. 
There are several parameters that can contribute as a source of errors for CV 
determination. For example, with the Nano-SPRi experiment a much lower concentration 
of analyte is being measured, the addition of NanoEnhancers adds another step in the 
procedure and the experiment was performed manually. A very good correlation between 
Nano-SPRi and ELISA was achieved for the detection of rhGh in spiked human serum. 
Finally, ELISA can be a reliable technique however the method itself is time consuming 
which makes it difficult to use in situations requiring real time monitoring and 
multiplexing, as it is the case with hGH. In addition, a more attractive feature that was 
not investigated directly in this study that SPRi offers over ELISA, is the ability to 
measure hundreds of interactions simultaneously in real time. Therefore in the future, 
Nano-SPRi method will be assessed to detect multiple biomarkers simultaneously in real 
time (multiplexing) present in serum at various concentrations in order to examine its 
potential as a viable clinical diagnostic tool.
3
                                                          
3
 This chapter is a reworked version of a published journal with reference Vance, S.A., Zeidan, E., Henrich, 
V.C. and Sandros, M.G. Comparative analysis of Human Growth Hormon in Serum Using SPRi, Nano-
SPRi and ELISA Assays. JOVE (in press).2015.  
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CHAPTER VI 
CONCLUSIONS AND FUTURE RESEARCH 
VI.1 Microwave Assisted Carbon Coated Nanoparticles 
In this study we presented a microwave assisted carbon coating procedure that 
was shown to coat small quantum dots and larger gold nanoparticles with great 
efficiency.   The use of microwave irradiation allowed for higher reaction rates which 
improves reproducibility and shorter reaction times.  The CEM microwave implements 
the controlled heating via wattage control and also provides greater control of 
temperature than that of conventional heating.   The greater control and higher reaction 
rates allowed for synthesis of a monodispersed quantum dots and surface 
functionalization of quantum dots and gold nanoparticles.  These benefits allowed for 
nanoparticles to be evenly carbon coated minimizing the toxicity that is inherent from the 
use of heave metal nanoparticles.  This reduction in toxicity will allow for further studies 
in the possible usage of nanoparticles in biological applications such as for in vivo and in 
vitro studies.   
VI.2 Improvement of SPRi Limit of Detection and Future Research 
After determining the benefits that microwave assisted coating of nanoparticles 
these benefits were applied to SPRi gold chip functionalization.  The implementation of  
microwave assisted functionalization of the gold chip allowed for more efficient coating 
as well as a greatly improved SAM formation with reduced defects. This implementation
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alone allowed for 2 fold increase in sensitivity as well as greater binding affinity of the 
aptamer to the analyte.  These benefits were seen in both the detection of CRP via 
aptamer sandwich and hGH via antibody sandwich.  The usage of an aptamer sandwich 
assay with nanoenhancers allowed for the detection of 5 fg/ml of CRP which was 
previously impossible to detect.  When directly compared to commercial ELISA kits the 
antibody sandwich assay with nanoenhancers was able to increase the sensitivity by 3 
orders of magnitude.  These levels of sensitivity will allow for the detection of 
biomarkers in concentrations that current diagnostic detection platforms are unable to 
detect at.   
These levels of sensitivity once expanded upon to many other biomarkers.  The 
imaging aspect of the SPRi would then allow for immobilization of multiple biomarker 
detection probes.  This platform would allow for the screening of multiple diseases 
ranging from detection of biomarkers for multiple forms of cancer to Alzheimers.   
Another benefit of the high sensitivity is that the test would require a small sample of 
blood (less than 1ml) while simultaneously screening for multiple diseases.  This would 
be unlike other methods in which diseases are tested for by using multiple assays that will 
each detect an individual biomarker.   
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